

Edited by Spanish Association of Bioenterprises (ASEBIO)

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including by photocopies, recordings or any information storage and retrieval, without written permission from the copyright holders.

© ASEBIO

1st edition: June 2010

Design: Margen

Photocomposition and impression: Gráficas Enar, S.A.

Legal deposit:


Executive Summary 2009


Executive Summary:

1. Situation of the Spanish biotechnological sector	6
2. New companies created in 2009	11
3. Business development activity	15
4. Industrial property and knowledge generation	19
5. Red biotechnology	21
6. Green biotechnology	23
7. White biotechnology	24
8. Financial environment	26
9. Internationalization	27
Appendix 1. Who is who – ASEBIO members	33



Executive Summary.





Executive summary

: Executive summary

1. Situation of the Spanish biotech sector

In 2008, the Spanish biotech sector consisted of 942 enterprises, which employed over 108,000 persons and the turn over was over 31,1 B€.

The last Survey on Companies' Technological Innovation (2008) (Table 1) revealed that the number of Spanish companies stating they use biotechnology doubled from 2005 to 2008. Thus, while in 2005 only 447 companies used biotechnology, this figure increased up to 942 in 2008. Likewise, the number of companies for which biotechnology is their main and/or exclusive activity (biotechs) experienced a striking evolution, increasing from 120 in 2005 to 305 in 2008.

Table 1. Main Results From The Biotechnology Module Of The Survey On Technological Innovation In Companies 2008


Main variables	Less than 250 employees	More than 250 employees	Total 2008	Total 2007	Difference	Growth Rate
Companies engaged in biotechnology-related-activities	861	81	942	764	178	23.3%
Companies for which biotechnology is the major and/or exclusive focus	287	18	305	257	48	18.7%
Companies for which biotechnology is a secondary business line	204	21	225	179	46	25.7%
Companies for which biotechnology is a necessary tool for production	370	42	412	328	84	25.6%
Companies engaged in R&D activities in the field of biotechnology	609	53	662	561	101	18.0%
Total employment	29,936	78,438	108,374	103,911	4,463	4.3%
Business income (million euros)	6,700	24,402	31,101	26,149	4,952	18.9%
Employees engaged in biotechnology R&D (total persons)	4,751	1,651	6,402	5,228	1,174	22.5%
A) Total by profession						
Investigators	2,526	1,012	3,538	2,946	592	20.1%
Technicians and assistants	2,225	639	2,864	2,282	582	25.5%
B) Total by gender (females)						
Investigators	1,346	574	1,920	1,635	285	17.4%
Technicians and assistants	1,294	440	1,734	1,428	306	21.4%



Main variables	Less than 250 employees	More than 250 employees	Total 2008	Total 2007	Difference	Growth Rate
Internal private expenses on biotechnology R&D (in k€)	317,090	143,563	460,653	376,146	84,507	22.5%
A) By expenditure item						
Overheads	246,288	139,972	386,260	294,385	91,875	31.2%
- Investigators' salaries	83,001	50,265	133,266	101,863	31,403	30.8%
-Technicians and assistants' salaries	51,841	25,438	77,279	54,854	22,425	40.9%
-Other overheads	111,446	64,270	175,716	137,669	38,047	27.6%
Capital expenditures	70,802	3,591	74,393	81,761	-7,368	-9.0%
-Land and buildings	26,418	80	26,498	8,870	17,628	198.7%
-Equipment and instruments	41,662	3,282	44,944	69,231	-24,287	-35.1%
-R&D specific software purchase	2,722	229	2,951	3,660	-709	-19.4%
B) By funding origin						
National funding	309,750	107,147	416,896	332,407	84,489	25.4%
-Own funding	202,847	93,378	296,225	215,092	81,133	37.7%
-From companies	15,620	6,090	21,711	25,637	-3,926	-15.3%
-From the government	88,021	7,629	95,650	88,813	6,837	7.7%
-From universities	258	0	258	290	-32	-11.0%
-From private non-profitable organizations	3,004	50	3,053	2,576	477	18.5%
International funding	7,341	36,416	43,757	43,739	18	0.0%
-From European Union programs	5,487	664	6,150	6,504	-354	-5.4%
-Other funding from abroad	1,854	35,753	37,607	37,235	372	1.0%
Companies applying biotechnology patents	11	11	11	11		
Number of patent applications	213	52	265	302	-37	-12.3%

Executive summary

Graph 1: Main Indicators' Evolution



Concerning the remaining indicators in the ASEBIO Report, the evolution has also been very favourable within the last three years (2006-2008), as shown in the Graphs 1 (above) and 2 (below). Thus, interannual growth rates have been of approximately 20%: for biotech-user companies (+23%), biotech companies (+19%), business income (+19%), internal R&D expense in biotechnology (+23%) or, for instance, for the number of companies engaged in R&D in the field of biotechnology (+18%). Moreover, in the context of the current economic crisis, the national biotechnology sector created 4,463 new jobs between 2007 and 2008.



The internal expenditure on biotechnology R&D was up to 460.65 million euros in 2008, which represents a 22.5% increase compared to 2007. These funds were mainly national (88.4%). More specifically, within the domestic arena, the national biotechnology sector R&D is financed predominantly by equity (64.7%), as well as by funds from the government (grants) (26.7%), and funds from other companies (7.7%), with the remaining funding coming from non-profitable private Institutions and Universities (this represents less than 1%).

Regarding the gender perspective, the percentage of women working in R&D within the domestic biotechnology sector is of 57%. In big companies with more than 250 employees, this percentage rose up to 61%, while in companies with less than 250 employees the percentage remained in about 55.5%.

The industry structure has remained virtually unchanged compared to 2007. SMEs represent the vast majority of the national bioindustry, especially in the case of




Executive summary 09


companies whose main focus is biotechnology. 94% of these companies have fewer than 250 employees. The business income and the jobs generated by this subset of SMEs account for 21% and 27% of the total respectively.

This atomization of the sector is due to the different profile of these knowledge-based companies. In most cases, you can find start up innovative companies that either have been born in the academic sphere (spin-offs) or are the result of a split from consolidated companies or groups of companies that have decided to diversify their business by going into more innovative areas while developing a new company (spin-outs). Furthermore, the high-level of specialization determines, to a certain extent, the size of these companies. With regard to the specialization area of these companies, 44% of the surveyed companies (Graph 3) stated that their main focus was on human health applications within the two major dimensions, i.e. therapeutics and diagnostics; and 36% stated to be engaged in the food sector. The survey results for the rest of technological areas were as follows: animal health and aquaculture (20%); agriculture and forest production (19%); environmental applications (18%); and other industrial applications (13%).

Graph 2: Number Of Companies Engaged In Biotechnology Evolution



Graph 3. Percentage Of Companies By Biotechnology End Application Area . Source: INE, Survey on Technological Innovation in Companies 2008




Executive summary


Indicator analysis by region

- Catalonia and the Community of Madrid continued to have the highest density of biotechnology-user companies and biotechs (mainly located in the urban areas of Madrid and Barcelona). Catalonia accounts for 22% and 21% of these companies respectively, presenting very high growth rates (13.7% and 16.4%, respectively), while the Community of Madrid brings together 17% and 23% of these two categories of companies. Particularly remarkable is the explosive increment in the Community of Madrid, wherein the number of user enterprises increased from 117 to 140 (+40%) last year, this increment being 21% for biotechs.
- Again this year, Andalusia and the Basque Region ranked third and fourth, respectively. Both regions continued to display great energy and enjoy double-digit growth rates in both parameters.
- The Community of Valencia, Galicia and Castile-Leon ranked in the next group, with average growth rates above 10%.

GRAPH 4. Geographical distribution of the companies engaged in biotechnology. Source: INE, Survey on Technological Innovation in Companies 2008



GRAPH 5. Geographical distribution of the companies with major focus on biotechnology. Source: INE, Survey on Technological Innovation in Companies 2008



Another variable that provides valuable information is the investment in internal R&D in biotechnology in a given region. This variable shows a positive correlation with the development of biotechnology in the region, which, in turn, can also be evaluated by the number of biotechnology companies located in a region.


Therefore, we have decided to display this variable together with the one showing the number of biotech – user companies for each region in the same graph (see Graph 6) in order to allow the joint evaluation of both parameters.

These results are consistent with the geographical distribution described above and show that the more a given region invests in R & D, more developed is its biotech industry. Similar findings would be made should this analysis be repeated with variables such as business income, employment, or, for example, joint profits from the regional sector.

Thus, the Community of Madrid and Catalonia show the best results in both parameters (close to the right upper vertex), followed by Andalusia and the Basque Region, which are also located in the quadrant with values above the mean. In the right lower quadrant, we find the Community of Valencia, Galicia and Castile-Leon.



Graph 6. Relationship of internal R&D expense and the number of biotechnology user companies.



2. New companies created in 2009

The following institutions from the different regions of Spain have collaborated in conducting this study: BIOTEGA, the Department of Economics of the Regional Government of Castile-Leon, General Directorate of Innovation of the Regional Government of La Rioja, BioBasque, Biocat, Sodena, Biocluster of Madrid, BIOVAL, CEEIs Alicante, Castellon and Elche, the General Directorate of Innovation of the Regional Government of the Balearic Islands, Canary Islands Special Zone (ZEC), PROEXCA, the Institute for the Promotion of Community of Murcia, the Agency IDEA, the Bioregion of Andalusia, Asturias BIC, Sodercan and Biocluster of Aragón (Bioartec).

In 2009, a total of 58 new biotech companies were created. The region with the highest number of new companies is Andalusia (26%), followed by Catalonia (24%), the Community of Valencia (9%) and the Community of Madrid (7%), and then Castile-Leon, Asturias, the Basque Region and Aragón (5% each).



Executive summary

Graph 7. Geographical distribution of biotech companies created in 2008. Source: ASEBIO.




Table 2. Companies engaged in biotechnology created in 2009. Source: ASEBIO

Company Name	Region	Activities
2B BLACKBIO S.L.	Madrid	Research, development, production, distribution and commercialization in Spain and abroad of medical and veterinary biotechnological products.
AB Therapeutics	Barcelona	Research and development of innovative pharmaceuticals for therapy of cancer and other indications.
Activery Biotech S.L.	Navarra	Research, development and/or production of pharmaceuticals or components for pharmaceuticals with high added value based on their own technology and entrepreneurial alliances with pharmaceutical companies.
Aeris	Barcelona	Design, manufacture and maintenance of bio-reactors for waste water and gas treatment.
ALPHASIP	Madrid	Design and development of R&D strategies for carbon nanotube assembly (CNT).
AMPbiotech	Girona	Development of synthetic antimicrobial peptides using natural compounds found in living beings as models.
Animal Breeding Consulting	Cordoba	Consulting and transfer of leading-edge technology to the livestock subsector in the field of genetic improvement, animal conservation and biotechnology.
AQP-INGREDIENTS S.L.	Murcia	Development of products of vegetal origin covering the demand from different sectors, such as food, cosmetic industry or surgery.
Bioalimentación Infantil de Andalucía	Cadiz	Research, development and commercialization of child foods from ecological agriculture. Development of ecological multifruit, multivegetable and meat jars of baby food.
BIOEMEDIA	Zaragoza	Bioinformatics
BIOINGENIA	Zaragoza	Bioinformatics
Bio-inRen S.L	Salamanca	Research, development and innovation in the field of kidney diseases.
Bionura	Barcelona	Development of neuroprotective agents for multiple sclerosis
Bioseguridad y Análisis Inmunológicos JAF S.L	Salamanca	Research, development and innovation in the fields of veterinary, medicine and food.



Executive summary 09

Company Name	Region	Activities
Biotech Solutions, SL	Almeria	Development and commercialization of new products based on biodegradable.
BioValora, Valorización de Residuos	Cadiz	Energetic and agronomic valuation of organic and/or biodegradable wastes through bioprocesses like anaerobic digestion and composting.
Celeromics Technologies,S.L	Valencia	Development, manufacture and commercialization of equipment and tools for data and image analysis in biotechnological and life sciences.
Corporación Biotecnológica IRIS, S.A.	Almeria	Research, production and commercialization of predators, parasites, parasitoids, pathogens and other natural biologic enemies for the control of plagues involving crops
Curaxys SL	Cadiz	Research, development, production and distribution of generic drugs and biosimilars
Desarrollos alimenticios por extrusión, S.A (DESALEX)	Asturias	Production of seasoned meat for hamburgers and other similar products from textured soy proteins (by extrusion) and other cereals
DESMOPLAT, S.L	Guipúzcoa	Design, development, production and commercialization of biotechnological regenerative solutions, as well as patent development, acquisition, sale, cession and licensing.
DIOMUNE S.L.	Madrid	Research, development and commercialization of new immune therapies, products and services with application in the area of human and animal health for infectious, inflammatory and autoimmune diseases.
Dosbio 2010,SLU	Sevilla	Research on the composition and chemical structure of starch and development of new and/or improved processes and products based on cereals.
EBERS	Zaragoza	Medical engineering. Design, manufacture, comercialization and distribution of equipment and products for cell cultures, including maintenance, as well as the whole range of related services.
Embryomics	Vizcaya	Non-invasive diagnostics of the pre-embryo.
Eyytoo Bioscience	Barcelona	Development of technologies for women's health: sexual dysfunctions, prevention and treatment of sexually transmitted diseases and contraception.
GIKA DIAGNOSTICS (Agrupación empresarial de interés económico)	Vizcaya	Technological development for preindustrialization of a portable microdevice for real-time selection of genetic material.
GREEN EARTH SOLUTIONS ESPAÑA	Las Palmas de Gran Canaria	Treatment and removal of non dangerous wastes.
Green Molecular	Valencia	Patented combination of two polyphenols capable of inhibiting metastatic growth and reducing the tumor activity of melanoma; in addition, it provides synergic effects in different applications in the fields of anti-ageing and dermatology.
Grupo Hesperides Biotech SRL	Sevilla	Development and commercialization of new, innovative, ecological, functional citrus drinks
HEALTHSENS S.L	Asturias	Development, manufacture and commercialization of high-sensitivity and -reliability electrochemical biosensors for diagnosis of several highly prevalent diseases.
IATEC	Cantabria	Brain analysis for improvement of human abilities.

Executive summary

Company Name	Region	Activities
iGenomix, S.L.	Valencia	Development of products related to biomedicina and diagnosis of disturbances in the field of genomics.
Immunovative Developments	Barcelona	Development of new biological therapies in the fields of sepsis and immune inflammatory diseases.
Instituto de Medicina Genómica, S.L-IMEGEN	Valencia	Biomedical company specialized in genetic analysis applied to the medical sector.
Janus developments	Barcelona	Development of early-stage investigational products for clinical development and commercialization.
Micelios del Sur, SL	Granada	Edible fungus farming during the whole year using only a type of substrate: the remains of olives left after olive oil production.
Microgenambiental	Almeria	Biotechnological microbial solutions
Microlitix	Barcelona	Hygienic solutions for food and pharmaceutical companies
MICRUX FLUIDIC S.L	Asturias	Development of miniaturized analytic systems for the agroalimentary, environmental and clinical sectors.
Nanoimmunotech S.L.	Pontevedra	Company specialized in the characterization and validation of nanoparticles prior to their use in in vivo human diagnostics and therapeutics.
Nanotherapix	Barcelona	Development of therapeutic agents for chronic inflammatory diseases.
Naturascope SL	Granada	Development of the multimedia portal Biovista.org for the sector of biotechnology.
Pangaea Biotech	Barcelona	Development of technologies for molecular diagnosis of cancer for treatment optimization.
Personal Digital Health Systems Spain	Granada	Development of reactants of kits containing enzymes compatible with the requirements of most big companies engaged in the area of genetic or epigenetic diagnostics.
Phycoelementa, SL	Almeria	Production of phycocyanin from spirulina
Probio Acuicultura SLL	Malaga	Provides the aquaculture industry with innovative products and services of quality from improved productivity. Integrated consulting, training, area of production, R&D projects in partnership with other companies and public entities.
ProRetina Therapeutics S.L	Navarra	Research and development of drugs for treatment of neurodegenerative and eye diseases.
Semiotrap, SL	Jaen	Integrated treatments for plagues
SEPROX BIOTECH, S.L.	Murcia	Research, development and production of nature antioxidants for application in high range products related to health and well-being.
SINERGIA BIO	Madrid	Development and exploitation of scientific projects aimed at generating cleaner and more environment-friendly for a sustainable development of our planet.
Som biotech	Barcelona	Development of new medical applications and indications of existing drugs.
Transmural Biotech S.L	Barcelona	Development of technologies for fetal endoscopy.
Trinity Technologies Europe	Barcelona	Production of animal serum of bovine origin for tissue cultures.
Valencia Biological Factory, SL.	Alicante	Development and manufacture of biological cultivations for agriculture and environment conservation.
VCN Biosciences	Barcelona	Development of oncolytic adenoviruses for cancer treatment.



Company Name	Region	Activities
Vivia Biosystems, S.L.	Valladolid	Screening and validation of candidate drugs with services to third parties for self-funding and development of their own R&D projects in specific therapeutic areas.
ZF BIOTOX	Cantabria	Development of drugs and drug safety assessment using the zebrafish


3. Business development activity

In this study on biotechnological companies' business, it is taken into account any formal agreement between at least one Spanish biotech company and any other company or institution involving an explicit commitment to accomplish common aims in different fields (e.g. R&D, production, sales, etc.) that has an impact on the strategy of the involved organizations.

The study includes different kinds of agreement (i.e. co-marketing, co-development, product and market exchange, etc), while conventional buying and selling and service provision relationships have been excluded. To gain a better view of Spanish companies' alliance policies, in the case of multinational corporations, in this study ASEBIO has included only those agreements in which the partner either is of Spanish origin or has a specific focus (distribution, sales, etc.) constrained to the national market.


In 2009, there were a total of 101 entrepreneurial alliances, of which 42% were signed by biotech companies and public entities, 38% by two biotech companies and 28% by a biotech company and a biotechnology user company.

Graph 8. Distribution of entrepreneurial alliances within the Spanish biotechnology sector by type of partner. Public partner/Biotech. Biotech/Biotech. Biotech/User company. Source: ASEBIO



Executive summary

In relation to the country of origin of the companies that signed the agreements as described above with the Spanish biotech, the percentages are as follows: Spanish companies (50%), European companies (18%), and U.S.A companies (13%). This indicates that there has been an increase in the number of agreements with foreign companies compared to 2008.




Graph 9. Distribution of Spanish biotechnology sector alliances in 2009 by partner origin. Spain. Europe. USA. Asia. Latinoamérica. Canada. Source: ASEBIO.

Product launching

For the third consecutive year, the present report includes a survey on the products and services launched to the market during 2009 by ASEBIO members.

The survey results show that a total of 38 products/services were launched to the market by these companies during the period of time mentioned above. This figure is considerable lower than the ones reported in previous years.

Human health continued to be the leading subsector (62%), followed by industrial processes (16%), human and animal health (14%), and animal health (8%).



Graph 10. Distribution of the products launched to the market by Spanish biotech companies during 2009 by application sectors. Source: ASEBIO.



Table 3. Products and services launched by Spanish biotech companies during 2009. Source: ASEBIO

Company	Product/service	Type	Area
A&B Laboratorios	DD 465 disinfectant cleaner	Industrial product	Industrial processes
AB-Biotics	AB-FORTIS	Product (functional food)	Human health
AB-Genotyping (AB-Biotics)	Neurofarmagen	Therapeutic product	Human health
Advancell	IsoCyp Tox TM: Cell reactant line to measure the toxicity of drugs and their metabolites	Industrial product	Human health
Advancell / Solvo Biotechnology	PreadyPort TM: Cell reactant line to measure cell transport of drugs and other compounds	Industrial product	Human health
Agrasys	Tritordeum (Vivagran®) Cereal with special organoleptic and nutritional characteristics	Product (functional food)	Human health
Biomedal Life Sciences	Kit LYTAG-2-PHASE for expression and purification of labelled proteins in water double phase	Industrial product	Industrial processes
Biomedal Life Sciences	Development of industrial bioprocesses for expression, separation and analysis of industrial and therapeutic proteins	Development service	Industrial processes
Biomol-Informatics	Next Generation Sequencing. Data analysis.	Bioinformatics services	Human health
Bionostra Aplicaciones Biotecnológicas	Healthcare center of Zebrafish	Diagnostic product	Animal health
Bionostra Aplicaciones Biotecnológicas	Promoter methylation analysis	Diagnostic product	Human health
Bionostra Aplicaciones Biotecnológicas	New studies on pharmacogenomics/ pharmacogenetics	Diagnostic product	Human health
BlackBio	Innovative technique for microsequentionation for routine diagnosis, pharmacogenomics and personalized medicine (First Kit: BlackLight Sepsis Kit)	Diagnostic product	Human and animal health
CIBER-BBN	CABs (Custom Antibody Service) integrated service platform for monoclonal and polyclonal antibody production	Development service	Human health
CIBER-BBN	Service platform for production of biomolecules: recombinant proteins, antibodies and peptides	Development service	Human health
CIBER-BBN	Service platform for production of biomaterials and nanoparticles for use in biomedicine	Development service	Human health
CIBER-BBN	Service platform for characterization of tissues, biomaterials and surfaces	Development service	Human health
CIBER-BBN	Integrated platform for analysis and treatment in vivo and ex vivo of images by MR, fluorescence and bioluminescence	Development service	Human health

Executive summary

Company	Product/service	Type	Area
CIBER-BBN	High-range integrated counting platform for experiments in silico	Research service	Human health
CIBER-ER	SEFAL-er (Service of Functional Studies in Laboratory Animals de Estudios)	Research service	Human and animal health
Farmbiocontrol	Dynamic system for control of emission of gases with greenhouse effect	Diagnostic product	Industrial processes
Farmbiocontrol	Implementation of automatized water- and energy-saving cleaning and disinfection systems with no chemical agents for the food sector	Industrial product	Industrial processes
Farmbiocontrol	Development of products base on 100% vegetal extracts for the control of emissions of gases with greenhouse effect and cointamination reduction in different areas	Research service	Industrial processes
Gendiag	Cardio inCode	Diagnostic product	Human health
Genomica	CLART FluAVir	Diagnostic product	Human health
Igen Biotech	Laboratory for R&D+innovation services	Research service	Human health
Ingenasa	DR assays for different infectious diseases	Diagnostic product	Animal health
Integromics	OmicsHub Proteomics (Integrated solutions for protein detection) and RT StatMiner Free Edition for data analysis of miRNA and RT-PCR	Software	Human and animal health
IUCT	New library for exopolysaccharides	Therapeutic product	Human health
Neiker-tecnalia	Technique for detection and identification of PSTVd (Potato Spindle Tuber Viroid) by PCR based on the EPPO PM7/33 method	Research service	Vegetal health
NorayBio	NorayBanks	Software	Human health
NorayBio	NorayLIMS	Software	Human and animal health
Operon, s.a.	Opegen LactoStrip – Diagnosis and prognosis of lactose intolerance	Diagnostic product	Human health
Pharma Mar, S.A.	Yondelis	Therapeutic product	Human health
Progenika	DNA LIPOchip biochip for diagnosis, prognosis and assessment of response to treatment in familial hipercolesterolemia	Diagnostic product	Human health
Sistemas Genómicos	Analytic system for early diagnosis of colon cancer in patients with polyposis	Research service	Human health
Veterindustria	Gui@Vet Guide of zoosanitary products of Veterindustria	Software	Animal health
X-pol	MagniPhi® (DNA polymerase)	Research service	Human and animal health



4. Industrial property and knowledge generation

Industrial property

The present study has been conducted based on the information contained in the following databases: Interpat (OEPM), Esp@cenet (EPO), PatFT and AppFT (USPTO), IPDL (JPO), PatentScope (PCT) and Aureka.

This year, the study has been extended to include all Spanish entities engaged in the biotechnological sector, and a great effort has been made to locate all the registers containing data on the BIO field.

In addition, the search has been expanded for patent applications and granted patents from the Japan Patent Office in order to measure the introduction of Spanish technology in the Asian market

During 2009, a total 430 inventions (applications plus granted patents), whose owners are Spanish biotechnology sector entities, have been identified. Moreover, it should be borne in mind that this figure would be considerably increased should some biotechnology-related entities, such as Esteve and Almirall, be included, as in 2009 these entities jointly accounted for 166 inventions (applications plus granted patents).

Table 4 shows the breakdown, in absolute value, of the 430 inventions according to patent protection coverage (Spanish, European, U.S.A., Japanese or PCT patents) and type of documentation (application or granting).



Table 4. Number of applications and grantings for patents whose owners are Spanish biotechnology. Entities (2009).

Patents*	OEPM	EPO	USPTO	JPTO	PCT	TOTAL
Applications	217	33	42	6	65	363
Granted	30	18	18	1	0	67
TOTAL	247	51	60	7	65	430


Eighty-four per cent of the inventions correspond to patent applications, of which 60% were processed through OEPM, followed by far by PCT applications (18%). This is a relevant information that is recorded in the present study for the first

Executive summary

time. As far as granted patents (16% of the inventions) are concerned, those processed through OEPM rank first (45%), followed by those processed by EPO and USPTO (27% each).

If one looks at the number of patent applications and granted patents submitted by Spanish biotechnological entities (Figure 1), one realises that the most active entity in 2009 in relation to industrial property is CSIC (65 inventions), followed by PharmaMar (41), and CIMA (37). Next, we have Palau Pharma (10), Natraceutical, and Oryzon (7), and ranking last Cellerix and Laboratorios Hipra (4 inventions each).

Graph 11. Spanish entities with the highest number of biotechnological patents (2009)



Scientific output

On a yearly basis, ASEBIO carries out an analysis of the publications from the Spanish biotechnological companies and Spain-based multinational research centres in high-impact scientific journals.

In the present study, oral communications and posters submitted to congresses or trade fairs and book chapters were excluded. Also, publications from Universities or Research Centers that were not related to studies aimed to entrepreneurial projects were excluded.

A total of 177 publications from 24 Spanish entities were identified. The most active entities were Biogen Idec (57 publications), Pharmamar (36), Grupo Progenika (20), Biotechnology Institute (12), Neocodex (8), and Sistemas Genómicos (5).



5. Red biotechnology (healthcare biotechnology)

Human therapeutics

In the area of neurodegenerative diseases we should highlight the drug Nypta from Noscira (Zeltia Group). In 2009, it was shown that this drug modifies the course of Alzheimer disease and was designated as an orphan drug to treat Alzheimer disease, both in the European Union and the United States.

In 2009, PharmaMar (Zeltia Group) gained European Commission authorisation to commercialise Yondelis in combination with doxorubicin to treat platinum-sensitive patients with recurrent ovarian cancer. Furthermore, Yondelis received eight new approvals outside the European Economic Area for the treatment of soft tissue cancer.

GP Pharm (Lipotec Grupo) launched Bicalutamide for advanced prostate cancer. Chimera Pharma completed animal model studies for its therapeutic vaccine against cervix cancer and its preventive vaccine that protects against all types of influenza.

The Centro de Investigación Médica Aplicada (CIMA) (Center for Applied Medical Research) made public novel therapies for liver cancer. CIMA identified two new molecules that inhibit tumor growth and prevent liver tumor growth.

The Banco Andaluz de Células Madre (Andalusian Stem Cell Bank) developed the first in-house stem cell lines, whilst the Fundación Inbiomed (Inbiomed Foundation) through its pharmaceutical laboratory Inbiopharma and cell bank (Inbiobank) started servicing biotech companies engaged in potential applications of stem cells.

Also, during 2009, Archivel Farma made public the results from a Phase I clinical trial of RUTI®, an innovative polyanti-genic drug for the treatment of latent tuberculous infection.

In the field of ophthalmology, we should highlight the following companies: AJL Ophthalmic, Biofarmik, Biolan, BTI, Faes Farma and Progenika Biopharma. The cooperative research center CIC bioGUNE and the technological center Inasmet-Tecnalia are taking part in the ongoing project Customatized Eye Care (CeyeC), the most ambitious CENIT project ever performed in the area of ophthalmology in Spain.



Executive summary



Human diagnosis

Araclon Biotech undertook the development of its kit Abtest, the only diagnostic kit currently available in the market for early-stage Alzheimer disease diagnosis. The kit discriminates between health individuals and those who present mild cognitive impairment or the disease with high sensitivity and reliability level. Next, Araclon Biotech will start the clinical phase of the trials for its Alzheimer disease therapeutic vaccine.

Oryzon, Laboratorios Reig-Jofré and Hospital del Vall de Hebrón are collaborating in a research project to develop a method for identification of biomarkers to enable the early diagnosis of endometrial cancer. Geadic Biotec, the joint company of Oryzon and Laboratorios Reig-Jofré, is the result of this collaboration.

Proteomika, together with Hospital de Cruces, has developed a new technique for the diagnosis of endometriosis, which is one of the leading causes of female infertility.

Animal health

In the area of animal health, we can find new companies engaged in a line of research aimed at manufacturing a biopharmaceutical product for dog leishmaniosis. Laboratorios LETI is now running a Phase III clinical trial for its protein Q, while Diomune, supported by Laboratorios Ovejero, is beginning a Phase III trial.

Palau Pharma and Global Veterinary Company are developing Cimicoxib (v.) for the treatment of inflammatory diseases and pain in pets. Currently, the product is in the Phase III of the development program.

Farm Biocontrol's portfolio includes biotech Dersuisan-vet, a product that is used to prevent and treating certain diseases like porcine exudative epidermitis, and Menforsan, an insect repellent of vegetal origin applied to animals.

Bioinformatics

Helios 2.0 by Intelligent Pharma uses bioinformatics, particularly computational solutions, to anticipate which molecules will have certain therapeutic properties against several diseases like AIDS. It consists of a ligand-based virtual screening tool. In addition, Intelligent Pharma is increasing the functionalities of HELIOS to enable the design of pharmaceuticals starting from scratch.

Bioalma launched Novoseek, a new biomedical search engine.

Noray Bioinformatics designed four new versions of its software NorayBanks, a software application that enables integrated management and drug traceability for biobanks and sample collections.



Biomol-Informatics released a detailed computational model of FtsZ, a bacterial protein related to tubulin. The model was developed by means of advanced molecular dynamic techniques, and describes in great detail the interaction between FtsZ and different molecules that are naturally associated. The model can accurately predict the actual behavior of the bacterial protein, which is closely related to human tubulin (a therapeutic target for a large number of anti-tumoral drugs used in chemotherapy).

The companies Integromics and Interna collaborate each other in the R&D+technological innovation project 'Andaomics', whose main objective is to develop a technological platform aimed at taking full advantage of the novel analytic techniques for genome (Next Generation Sequencing, NGS) and protein (proteomics).

6. Green biotechnology


Agriculture and forest production

Spain continues to be the largest GMO producer, with a total of 76,000 hectares, which accounts for 80% of the surface area of BT corn in the European Union, and a record adoption rate (22%), ranking fourteen in the world as a GMO producer.

In 2009, scientists from the University of Lleida developed a hypernutritious transgenic corn that includes vitamins A and C and folic acid, and, in turn, the company Monsanto is developing a liquid soy oil with omega-3.

The Instituto de Biotecnología de la Universidad de Granada (Biotechnology Institute of Granada University) developed a bioinsecticide for control of the Mediterranean fruit fly plague, and GMW Bioscience is conducting several studies on the biological efficacy of an endoparasitic fungus that controls the phytoparasitic nematode pathogenicity (worms that penetrate the plant roots and cause malformations, even the plant's death).

Currently, NEKER-Tecnalia through its Department of Biotechnology is testing the pinus radiata material obtained from in vitro cultures. Preliminary results support the project feasibility. Also, this company has recently undertaken a research project to genetically characterise oak trees with the aim of identifying hydric stress-resistance genes.



Executive summary

Functional food

According to the European Food Safety Authority (EFSA), since 2007 functional food consumption has been growing at a rate of 15% in Europe annually. This figure is in accordance with the research volume of Spanish biotech companies in the field of functional food for health improvement.

During 2009, Neocodex investigated functional foods with potential application in neurology, Biotmicrogen has continued investigating a new probiotic stump with immunomodulatory properties, and the company Ingredientis Biotech developed a compound found in legumes to fight against coronary diseases.

The companies Neuron BPh, SOS-Cuétara and COVAP set up the integrated project Al-Andsalud with the aim of developing alimentary solutions for special nutrition requirements, particularly those with application in the field of neuro-degenerative and cardiovascular diseases.

The Instituto Biomar (Biomar Institute) is finishing a project aimed at identifying new natural preservatives, and another study on new prebiotics is well under way.

AB BIOTICS currently has in its pipeline 12 probiotics and food supplements for health improvement, with 11 of them in the investigational stage (AB LIFE, AB-13.1, AB-INTIMUS, AB GINGIBAL, AB-HALITOSIS, AB-COLIC, AB-PROBIOSIS, AB-VITAMIN-K, AB-RADIOBAL, AB-PYLORIOSIS, AB-ENHANCER) and one in market launch stage (AB FORTIS).



Food control technologies

Savia Biotech launched a series of DNA techniques-based technologies for identification of genes and pathogens, such as the pepper parietary, whitefly, bronzing virus, cockroach virus or tomato mosaic virus. Additionally, the Valencian company Biopolis employs the worm *Caenorhabditis elegans* as a validation platform for functional food ingredients intended to fight against obesity or ageing, or with properties that make them suitable to prevent Alzheimer disease.

7. White biotechnology (industrial biotechnology)

Biotechnological applications to energy production


The Plan for Renewable Energies 2011-2020 of the Spanish Ministry of Industry, Trade and Tourism contains provisions for 2020 mandatory targeted objectives concerning renewable energies for both the EU as a whole and each member state. This has spurred Spanish biotech companies to increase the number of research projects into biofuels.



During 2009, the companies Repsol and Abengoa Bioenergy set up projects within this area. The latter, in partnership with Biopolis, NorayBio, Solutex and Oryzon, is engaged in a project entitled "Bioenergetic Assessment of Agroalimentary Wastes".

The Granada-based enterprise Neuron BPh and the company IUCT independently developed two different, though compatible, methods for producing biodiesel from glycerin.

Several entities are working on new methods for producing biofuels from waste materials. Thus, University of Jaen is investigating the production of biofuels by extracting energy from the olive tree pruning; the Technological Center of Adesva focuses on taking advantage of waste materials from orange pulp and peel; Ecologic Biogas uses the pruning wastes; the company Amolí uses waste gardening products grown in the area of Lleida; Bioaurum investigates the exploitation of organic waste fermentation for production of biogas; and Microgenambiental (Biot Group) is developing and marketing new microbial strains producing biodiesel from organic waste.



In addition, there are other companies that have chosen to use microseaweeds for producing biofuels. Such is the case of the Institute Biomar, Biofuel Systems, AlgaEnergy, which possess the exploitation rights for the species *Anabaena* and *Muriellopsi*, NEIKER-Tecnalia and the Instituto Vasco de Investigación y Desarrollo Agrario (Basque Institute for Agricultural Research and Development).

In 2009 the company Synergia bio (Bionostra Group) was set up. Currently, this company is developing several projects for the identification and manipulation of genes capable of modifying cellulose-rich cell walls.

It is worth underlining the opening of Sangüesa (Navarra), a biomass plant that produces biomass from wood shavings and kindlings, the construction of the bioethanol demonstration plant located in Babilafuente (Salamanca) (cereal straw), and the construction of the biggest biomass plant in Europe located in Navalmoral de la Mata (Caceres) by the Spanish company Desarrollos Rurales El Encinar.

Bioremediation and biodetergency

In 2009, the Seville-based company Morell Innova launched a product made by means of biotechnological techniques that recovers drought-damaged trees, clears contaminated soils, saves water and plaguicides, and increases productivity.

Currently, the company Microgenambiental is participating in an ongoing project to develop a profitable, efficient, innovative and sustainable system for in situ treatment and reutilization of contaminated water generated during the olive washing process by farming cooperatives producing olive oil.

Executive summary

The company ABBA Gaia has created a revolutionary genetically-improved vegetable variety for removing heavy metals that cause soil contamination. This variety (*Nicotiana glauca*) possesses a natural property to absorb metals and, therefore, to eliminate soil contamination. Scientists from the Technical University of Valencia have been able to make this variety up to thousand times more efficient by adding a wheat cloned gene.

In 2009, the company Solutex through its subsidiary company Nanotex has begun launching ecological solutions in the form of zero-valent iron nanoparticles. At the end of 2009, the company set up an ongoing project in order to improve the product for specific contamination problems and better applicability.

Also, the company A&B Laboratorios de Biotecnología (A&B Biotech Laboratories) is investigating new enzymes and microorganisms for biodetergents under the name of Bioclean.

Biopolymers and bioplastics

Neuron BPh has developed a technological platform called Microbiotools® that enables the fast selection from a collection of the microorganisms that are able of conducting industrial processes in an effective and environment-friendly manner. Among the platform applications, the company highlights TriBioPlast®, a novel solution for the exploitation of the alperujo and other by-products from olive oil extraction plants for the production of bioplastics.

Arquebio, in turn, is now engaged in the industrial-scale modification process of polymers for cosmetic applications, and the Centro Nacional de Tecnología y Seguridad Alimentaria (CNTA) (National Center for Food Technology and Safety) is developing a project for biodegradable plastic production.

8. Financial environment

Among the operations carried out by private entities during the last year, we should mention Cellerix (Genetrix Group), leading the ranking with a total amount of 27.2 MM (euros) raised in a financing round with first class national and international investors. It is the third international financing round for this Spanish company focused on the development of stem cell based drugs, and in this operation have participated the following companies: Ysios Capital Partners, Life Science Partners, Ventech, Bankinter, Capital Riesgo Madrid and JV Risk Technologies, with the key contribution of Grupo Genetrix.

The second largest financial operation in the year, though it was signed at the beginning of 2010, was conducted by the biopharmaceutical division of the Lipotec Group, GP-Pharm, through a syndicated loan. This operation ran to 20 MM.

According to the Spanish Risk Capital Association (ASCRI by its acronym in Spanish), the sectors receiving the largest volume of risk capital investment du-



ring 2009 were Energy, Natural Resources and Consumer Products, with Biotechnology & Genetic Engineering ranking ten (3.7%). On the other side, Biotechnology ranked second after Computing (24%) in the number of operations (11%) undertaken in 2009, and in the early-stage investment segment Computing (20.5%) and Biotechnology/Genetic Engineering (10,2%) stand out, as well as for the number of operations.

2009 was an outstanding year because of the increased number of specialized companies that have invested in biotechnology, such as Inveready Seed Capital and Cross Road Biotech.

Another outstanding operation in 2009 was the acquisition of 35.11% of the issued share capital of Naturex by Natraceutical.

9. Internationalization

Herein, we go into detail on the most relevant results and conclusions from the second survey on internationalization of ASEBIO associated companies during 2009.

Approximately 35% of these companies had international activity in 2009, which represents a 5% increment in relation to the previous year. The most common international activities were product or service exportation, participation in the 7th Framework Programme (EU) and alliances/collaborations for research, with an annual international turnover of 500 million euros. In 2009, the contribution of international business of ASEBIO associated companies averaged 26%.

According to data from the survey on internationalization, in 2009, 31% of the companies had an international business department or staff. The staff engaged in international business averaged 21% of the total. In addition, most companies that increased their staff in 2008 also increased the personnel involved in international business in a more than proportional manner.

The lack of economic resources was mentioned by 100% of the surveyed companies as the most common barrier to internationalization. Less frequently, these companies mentioned the need to contact with intermediate professionals specialized in valuation of patents and licenses, product registration and specific training for the staff involved in international business.

To compensate for the lack of specific training, companies think they need to focus in particular on the negotiation, patents and international market research training as international business topics.

The markets that the companies surveyed have considered as priorities for their internationalization strategies, and for the sector as a whole, were almost at the same rate, the Member States of the European Union, mainly the United Kingdom, Italy, Germany, Portugal, France and Scandinavia, as well as the United States, and in a second group, Canada, China, Brazil, Japan or India.



Executive summary

Table 8. Preferred markets for internationalization strategies of Spanish biotech companies (% of the total of answers)

1.	European Union	83%
2.	United States	73%
3.	Canada	32%
4.	Brazil	23%
5.	China	21%
6.	India	18%
7.	Japan	15%
8.	Argentina	12%
9.	Chile	12%
10.	Switzerland	12%
11.	Malaysia, Oman...	

The preferred procedure for ASEBIO members for a first approach to foreign markets and commercial development in them was the participation in partnering events and attendance to trade fairs, with more than 60% of the surveyed companies considering such activities very relevant for their internationalization strategies.

For these companies, the type of activity they would like to develop in the future with companies / institutions operating in international markets is primarily the export of products and / or services, transfer of technology and search for investors

Among the international biotech events that the surveyed companies regard as the most relevant we can find the Bio International Convention, BioEurope, BioEurope Spring and Biospain.

All the surveyed companies that have not started yet their international activities reported that internationalization is an important or fundamental step, and 61% stated that internationalization is a short-term priority, while the remaining 39% reported that, because their entrepreneurial project was still young, they have opted to consolidate their position in the national market before leaping outside.

Thus, internationalization has become a priority for Spanish biotech, going from sixth to first place in their priorities for 2010.

Overseas investment

ASEBIO member companies try not only to increase their international turnover through product and service export, but also by investing in foreign countries, while establishing their own subsidiaries, offices or business representations.

Currently, our companies have direct presence in a total of 26 countries in North America, South America, Europe, Asia and Africa.



Graph 12: ASEBIO member companies' international presence

COUNTRY	SUBSIDIARIES	COUNTRY	SUBSIDIARIES	COUNTRY	SUBSIDIARIES
USA	10	UK	2	DOMINICAN REP.	1
BRAZIL	6	CHILE	1	SINGAPORE	1
MEXICO	6	COLOMBIA	1	SWEDEN	1
PORTUGAL	6	ARAB EMIRATES	1	THAILAND	1
GERMANY	5	FRANCE	1	TURKEY	1
ITALY	5	JORDAN	1	URUGUAY	1
ARGENTINA	4	MALAYSIA	1	VENEZUELA	1
POLAND	3	MOROCCO	1		
CHINA	2	CZECH REP.	1		



Most of the offices opened abroad by ASEBIO member companies are concentrated in the European Union (37.5%) and Latinoamérica (33%). The geographical closeness and the similarity of the legal framework in the case of Europe, and the common language and cultural proximity in the case of Latinoamericano explain these data.

At any rate, in only one country, i.e., the United States, there is 16% of the total number of subsidiaries since this country is the most important biotech market worldwide.


Executive summary

International alliances

International alliances represent one of the most relevant aspects for internationalization of biotech companies. Thanks to these alliances, companies and institutions are able to minimize the risks and have access more easily to resources, knowledge and new technologies.

A total of 22 ASEBIO associated companies signed 40 international alliances in 2009, thus increasing the figure for the previous year (+74%). This data includes any type of formal agreement between at least one Spanish biotech company and any foreign entity involving an explicit commitment to accomplish common objectives, such as output, sales, R&D, and so forth.

Graph 13. Evolution of the number of international alliances signed by ASEBIO associated Spanish biotech companies.




The majority of such alliances were signed with companies/institutions located in the European Union (40%) and the United States (35%), followed by companies/institutions located in Asia (15%), Latinoamérica (5%) and the rest of Europe (5%).

It should be emphasized that most companies (73%) participating in an international alliance have not been established abroad yet, which confirms that international alliance is only a first step in the internationalization process.

Ninety-five percent (95%) corresponds to companies located in the Community of Madrid (45%), Catalonia (30%), Basque Region (12.5%) and Andalusia (7.5%), which approximately reflects the geographical distribution of Spanish biotech enterprises.



Graph 14. Geographical distribution of international alliances signed by ASEBIO associated Spanish biotech enterprises/institutions in the period 2005-2009.



The following list includes ASEBIO associated companies with subsidiaries, offices or bussiness representations in foreign countries:

- Alphasip: U.S.A
- Biokit: U.S.A.
- Biotoools: Brazil
- BTI Institute: U.S.A.; Mexico, Portugal; Italy; Germany
- Grifols: Germany, Czech Rep.; Argentina; Singapore; Mexico; Brazil; Chile; Portugal; Italy; UK; France; Malaysia; Thailand; Poland
- Juste: Mexico, Argentina; Brazil
- Grupo Farmasierra: Portugal
- Laboratorios Leti: Germany; Portugal
- Noray Bio: Italy
- Laboratorios Calier: Portugal, Italy, Poland, Argentina, Brazil, Colombia, Mexico, Uruguay, Venezuela, Morocco
- Esteve: Germany, U.S.A., Italy, Portugal, Mexico, Turkey, China, Sweden
- TPRO: China, Argentina, Brazil
- Thrombotargets: UK, U.S.A.
- Probelte: Mexico, Dominican Rep., Brazil, Poland, Jordan
- Progenika: U.S.A. / Arab Emirates
- Pharmamar: U.S.A.
- Neocodex: U.S.A.
- Integromics: U.S.A.
- Intelligent Pharma: Germany
- Solutex: U.S.A.

A1.

Appendix 1 Who is who?





A1. Who is who?

Company Members



3P BIOPHARMACEUTICAL, S.L

Mission > To offer comprehensive products and services of high quality and added value to our customers, satisfy our investment partners, and achieve the well-being of our employees.

Products > Monoclonal antibodies. Biosimilars. Human cells culture. Cell therapy and gene therapy. Protein expression systems and other process. Stability trials. Analytical developments.

Interest areas > Enterprises with a pipeline that needs a CMO as 3P. High technology partners that could implement 3P capabilities. Specific financing for specific projects. Industrial GMP facility of cell therapy. Industrial GMP facility of grub insect technology. Others.

Contact > TEL: 948 346 480
www.3pbio.com

Dámaso Molero.
dmolero@3pbio.com



3T SCIENCE, S.L.

Mission > Investigation of new technologies and development of new products, tools or systems orientated to meet the most significant demands of the biotechnology market, and also to facilitate the development of a new generation of technologically advanced products and to improve those already in existence.

Products > Tools for the production of biomolecules in specific sub-cellular compartments. New biomolecules. Pipeline. Advanced products.

Interest areas > Projects destined to improve significantly the performance and the efficiency of the production of biomolecules, to allow access to new biomolecules with a therapeutic function (enzymes, receptors, GPRCs) and/or with a high interest level (bioconservants, biocatalists), and to contribute new technological innovations to attend specific demands (biosensors, bio-recycling, biofuels).

Contact > TEL: 955 027 949
www.3t-science.com

Moisés Álvarez Maqueda
malvarez@3t-science.com



A & B LABORATORIOS DE BIOTECNOLOGÍA, S.A.U.

Mission > Development of bioproducts for biodetergents and bioremediation products.

Products > Chemical and biological products (bio-detergents, products for bio-remediation and purification, etc.) for professional use. Using biotechnology, ecodesign and Ecolabel criteria, A&B Laboratorios de Biotecnología puts solutions cleaner and safer on the market.

Interest areas > Selection of natural micro-organisms. Enzyme production. Industrial fermentation. Ecodesign.

Contact > TEL: 945 291 616
www.ab-laboratorios.com

Jon Kepa Izaguirre
(Director de Gestión)
kepa@ab-laboratorios.com



Who is who?

**AB BIOTICS, S.A.**

Mission > Research and develop protected biotechnology solutions to improve the health and welfare of people.

Products >

- Nutraceuticals: AB-FORTIS (cognitive development of children) AB-LIFE (improvement of cardiovascular health) and AB-13.1 (a probiotic for IBD/IBS).
- Pharmaceuticals: ABT-1 (AB-THERAPEUTICS) (membrane lipid therapy for oncology). Genomics: Neuropharmagen (AB-GENOTYPING) (pharmacogenomic solution for neuropsychiatric disorders).

Interest areas > AB-BIOTICS is interested in developing biotechnological products for human health. Our main objectives are functional genomics and nutraceuticals. We are always open to set up synergic partnerships with other companies in order to jointly develop new solutions.

Contact > TEL: 902 903 844
www.ab-biotics.com

Miquel Angel Bonachera (CEO-CFO)
Miquel@ab-biotics.com



Medical & Science

ADECCO MEDICAL & SCIENCE

Mission > Provide HR services for the medical, science, pharmaceutical and biotechnology industries such as search and selection services of specialized profiles, specialized training and HR consulting with a proven know-how within each area.

Products > Search and selection services for medical & science profiles focused in research, sales and marketing activities within the pharmaceutical & biotechnology sectors. Technical training consulting for the pharmaceutical and science areas. Occupational health & safety consulting.

Interest areas for futures colaborations/alliances > Participation in working groups, publications and workshops. Provide business solutions to different needs in the HR area.

Contact > TEL: 932 722 870
www.adecco.com

Oscar Porcel (Consultor)
Oscar.porcel@adecco.com

A1. Who is who?

Company Members



ADVANCELL ADVANCED IN VITRO CELL TECHNOLOGIES, S.A.

- Mission >** ADVANCELL is a biotechnology company with its own technology and continuous innovation; it deals with unresolved questions in health and wellbeing. The company is organized into three Units: Alternative Testing (cell-based in vitro models). Nanosystems (natural polymer nanosystems to improve the administration of drugs). Therapeutics (development innovative drugs, result-oriented for new applications)
- Products >**
- ReadyCellTM: ready-to-use cell-based assay kits (CacoReadyTM, CacoGoblet, IsoCypTM-Tox & PreadyPortTM-MDR1)
 - Drug Delivery Technologies: chitosan-coated nanocapsules; nanoparticles of chitosan and other compounds & PLGA-poloxamer nanoparticles.
- Services >**
- Screening and customized research mainly in ADME-Tox and cosmetic areas.
 - Development of prototypes using chitosan nanosystems technology.
 - Development of new drugs up to clinical proof of concept.
- Interest areas >** Out-licensing of molecules in early stages of development with an strategic value for ADVANCELL. Collaboration on development of prototypes using nanosystems technologies in oral, topic or nasal applications. Development of new cell-based assay kits to ADME-Tox applications.
- Contact >**
- | | |
|---------------------------------------|--|
| TEL: 934 034 545
www.advancell.net | Kenneth Weissmahr
ken.weissmahr@gmail.com |
|---------------------------------------|--|



AGRASYS, S.L.

- Mission >** AGRASYS is a R&D-based company which uses advanced plant breeding technologies to produce novel crop varieties with added value. These new varieties are targeted at specific market opportunities, identified by the company or its business partners. Current projects and products of the company are directed at the market sectors of functional foods and biofuel crops.
- Products >** The first product being brought to market is a novel cereal type which offers health benefits and can be used in the production of a range of cereal-based foods. The same techniques are used in the development of improved food crop varieties for bioethanol. The company has experience of consultancy in the Ag-biotech area.
- Interest areas >** Agrasys works with companies and public research centers, as the technology provider, contractor of research services or partner in product development and marketing. Examples of collaborations; breeding of new crop germplasm as raw material for food or industrial uses, co-development of new food applications based on varieties with functional components, genetic engineering of industrial crops.
- Contact >**
- | | |
|------------------------------------|---|
| TEL: 934 020 278
www.agrasys.es | Pilar Barceló Ensena
pilarbarcelo@agrasys.es |
|------------------------------------|---|



Who is who?



ALEXION PHARMA SPAIN, S.L.

- Mission >** Pharmaceutical product development and commercialization.
- Products >** Humanized monoclonal antibody for the treatment of the Paroxistic Nocturnal Hemoglobinuria
- Interest areas >** Biotechnology applied to general medicine. Innovative drugs. Orfan drugs commercialization in rare diseases
- Contact >** TEL: 932 723 005
www.alxn.com

Jordi Casals
casalsj@alxn.com



ALMA CONSULTING GROUP ESPAÑA

- Mission >** Our mission is to identify and obtain financing and savings for our customers. We contribute to our clients competitiveness through measurable actions.
- Products >** Areas of expertise: Innovation Financing. Propety Tax. Overhead Expenses: tel-econs, electricity, office cleaning, travels, etc.
- Interest areas >** We create a long-term partnership with our customers in order to provide an outstanding support to improve their results.
- Contact >** TEL: 915 750 301
FAX: 914 355 386
www.almacg.es

Marta Orueta
morueta@almacg.com
Juan Antonio Costa
jacosta@almacg.com



ALPHASIP

- Contact >** TEL: 915 223 828
www.alphasip.es

Miguel Roncales
mroncales@alphasip



AMGEN, S.A

- Mission >** To serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or even save lives.
- Products >** Oncology and hematology treatments. Amgen is developing research programs in nephrology, hematology, oncology, inflammatory diseases, metabolism and neuroscience.
- Contact >** TEL: 936 001 900
www.amgen.es
www.amgen.com

Juan Carlos Esteban
jesteban@amgen.com

A1. Who is who?

Company Members



ARACLON BIOTECH, S.L.

Mission > Research and development of neurodegenerative diseases therapies and diagnostics methods.

Products > Under development: Alzheimer disease blood diagnostic tests. Alzheimer disease therapy.

Contact > TEL: 976 796 562
www.araclon.com

Guillermo de Vilchez Lafuente
gdevilchez@araclon.com



ARCHIVEL FARMA, S.L.

Mission > Discovery and initial clinical development of novel pharmaceutical agents of biological nature.

Products >

- RUTI®, poly-antigenic vaccine made of fragments from Mycobacterium tuberculosis, detoxified, and formulated with liposomes.
- RUTI® is in phase II of clinical development for the prevention of active tuberculosis in individuals with latent tuberculosis infection (therapeutic use).
- RUTI® is as well under evaluation for its use in the treatment of active tuberculosis and in other therapeutic areas.

Interest areas > Prevention and treatment of tuberculosis with biological agents. Diseases or pathological conditions that could benefit from immunomodulatory treatments.

Contact > TEL: 934 972 456
www.archivelfarma.com

José Luis Cabero
archivel@archivelfarma.com



ARQUEBIO, S.L.

Mission > ARQUEBIO S.L. was created in 2007 by a highly experienced team in industrial life-sciences and chemistry with great R&D+i network. The company offers alternatives to industrial chemical synthesis processes through developing bioprocesses based on microbial fermentation. Own research and contract research and a collaborative approach allows offering state-of-the-art knowledge and profitable technology transfer to industrial customers.

Products > Chem to Biotech (C2B) implies the substitution or modification of traditional chemical synthesis reactions by biotechnological approaches, which comprise either the use of wild type and recombinant bacteria, yeasts and molds, or their products, such as enzymes. Nanotechnology for Biomedicine (N4B) takes profit of the same technological platform to obtaining products by fermentation (recombinant proteins and polymers) and develop delivery systems for drugs (Drug Carriers) and nucleic acids (Gene Therapy). These Delivery Systems can improve efficacy and decrease secondary effects in Oncology, Neurodegenerative diseases and other therapeutic fields.

Interest areas > Chemical, cosmetic, pharmacy, biotechnological and veterinary companies interested into introducing biotransformations in their manufacturing processes or interested in the evaluation and development of new approaches based on products obtained by microbial fermentation. ARQUEBIO collaborates with private and public research groups.

Contact > TEL: 935 868 926
www.arquebio.com

Jaume Mir Ph.D (CEO)
jaume.mir@arquebio.com



Who is who?



ARTBIOCHEM, S.L.

- Mission >** Investigation and development of new enzymes and biomolecules. Development of new test for determination and quantification of metabolites using artichoke peroxidase.
- Products >** Peroxidase, Protease, High DP Inulin, Polyphenol Extract from Artichoke. R+D Services from extraction and purification of enzymes and others biomolecules.
- Interest areas >** Development of new applications from high Dp inulin in biomedical sector. Development of tests for clinical diagnostics with companies of this sector for the detection of different diseases. Associates' search for the distribution of our products. Bioremediation. Microbiology y Fermentation.
- Contact >** TEL: 968 688 229
www.artbiochem.com
- Jose Luis Vidal
jlvidal@artbiochem.com
Francisco Palazón
fpalazon@artbiochem.com



BAYER BIOSCIENCE N.V

- Mission >** Bayer Bioscience N.V. is one of the main biotech innovation centres of Bayer CropScience AG, a subgroup of Bayer AG. The objective of the excellence centre is to integrate plant biotech research with the business demands of Bayer Bioscience to optimise innovating processes in a responsible and sustainable way. Drawing up crop management solutions (pest and weed control), researchers use genetic engineering to discover new features.
- Products >** Patents, know how. Crops of high agronomic interest, with new features applied to modern crossing techniques.
- Interest areas >** Agriculture, Environment-Biotechnology
- Contact >** TEL: 92 430 468
www.bayercropscience.com
- Maica Martínez
maica.martinez@bayercropscience.com



BIOALMA

- Mission >** Bioalma's objective is the development of information systems that help the researcher in biomedicine to manage and analyze the information in the literature, to research more efficiently and to reduce the development time of new products
- Services >** Novoseek is a biological knowledge system that manages information extracted directly from the scientific literature using the most advanced text mining techniques. It provides powerful search and visualization capabilities to navigate the knowledge network and contains functionality to easily identify relevant information.
- Interest areas >** Bioalma is interested in the application of information technology techniques on other biomedical bibliographic sources different from the scientific literature and the collaboration with biotech companies for the development of product that use information extraction for target discovery and validation and functional analysis of groups of genes or proteins.
- Contact >** TEL: 911 417 150
www.bioalma.com
- Luis Cornide
lcornide@bioalma.com

A1. Who is who?

Company Members



BIOAURUM SOLUTIONS, S.L.

Mission > Technology Transfer and Innovation Management in Life Sciences. Spreading biotechnology uses in traditional sectors and in rural areas.

Services > Strategic Consulting in Life Science Sector. Designing public policies in Biotechnology sector. Managing Private-Public consortium.

Contact > TEL: 913 197 603
www.bio-aurum.com

Fidel Rodríguez Batalla
froba@bio-aurum.com



BIOBIDE, S.L.

Mission > Biobide is a biotech company that aims to help our customers worldwide developing tailor-made solutions to maximize R+D productivity and minimizing risks in the Drug Discovery process, integrating zebrafish animal model with innovative tools, adding value to their R+D+i mainly in the preclinical area (toxicology, safety and efficacy).

Products > Capabilities for tailor-made solutions: Target validation. Transgenesis and disease model generation. Customized assay. TOXICITY: Specific toxicity Assays: Cardiotoxicity: Cardiotox assay. Teratogenesis: Teratox assay. Ototoxicity: Ototox assay. Hepatotoxicity: Hepatotox assay. General toxicity Assays: Acutetox assay. EFFICACY: Oncology: Angiogenesis inhibition assay. CNS/Neurodegeneratives: Alzheimer assays.

Interest areas >

- Collaboration agreement with pharmaceutical and biotechnology companies with the aim of developing assays, increasing its value by means of this synergy collaboration.
- Company policy consists on setting up agreements with agents that possess quality research capacity and undertake applied research projects complementary to our company's activities, maximizing therefore the investment on all fronts.

Contact > TEL: 943 309 360
www.biobide.es

Idoia Ruiz de Azua
ruizdeazua@biobide.es



BIOFTALMIK

Mission > Our main objective is to design and develop diagnostic, prognostic and therapeutic systems for eye diseases and Biodevices for ophthalmic surgery.

Products > Integral R&D platform. Diagnostic tests. Clinical trials.

Interest areas > Our strategy clearly promotes scientific, technical and clinical collaboration and all its manifestations as the most effective ways to innovate. Our main areas of interest are: Ophthalmology, therapy, diagnostic, prognostic, cell culture, molecular biology, proteins, drug development and drug delivery.

Contact > TEL: 944 069 659
www.bioftalmik.com

Jon Careaga
Jon.careaga@bioftalmik.com



Who is who?

biogen idec

BIOPEN IDEC IBÉRICA, S.L.

Mission > We create new standards of care in neurology, oncology and immunology through our pioneering research, our global development, manufacturing and commercial capabilities.

Products > TYSABRI® (natalizumab) is a treatment approved for relapsing forms of MS in the United States and relapsing-remitting MS in the European Union. AVONEX® (Interferon beta-1a) has the most treatment experience for relapsing forms of MS worldwide, with more than 135,000 patients on therapy. It is used worldwide as a treatment for relapsing forms of MS to slow the progression of disability and reduce relapses.

Interest areas > At Biogen Idec, we believe strongly in the value of successful partnerships, and we do everything we can to make them work. If your company is in the later stages of development, Biogen Idec can provide a wealth of resources to help successfully commercialize your product. We are interested in partnerships in our core therapeutic areas, which include neurology, oncology and immunology. In addition, we welcome products in acute care, including cardiovascular, hemophilia, infectious disease, and other products used in a hospital environment. We also have active programs in hemophilia research and development. In fact, we are open to partnerships in additional therapeutic areas that lend themselves to a specialty biopharma business model.

Contact >	TEL: 913 107 110 www.biogenidec.es	Guido Decap Carrasco guido.decap@biogenidec.com
---------------------	---------------------------------------	--

bioges
starters

BIO-GES STARTERS

Products > Starters for the agricultural and food industry

Contact >	TEL: 987 876 135 www.bioges.es	Agustín Florez Moran marian@serfisa.es
---------------------	-----------------------------------	---

biokit

BIOKIT, S.A.

Mission > Development, production and commercialization of immunoassays for the clinical diagnostics (IVD) market.

Products >

- Serology reagents for the diagnosis of infectious diseases and for the detection of plasma proteins. Manual assays (latex agglutination, hemoagglutination, immunochromatography), ELISA assays and assays for automatic platforms (immunoturbidimetry and chemiluminescence). OEM services: Contract development and manufacturing of immunoassays for clinical chemistry, immunochemistry and coagulation applications. Raw materials: Polyclonal and monoclonal antibodies. High-quality natural and recombinant antigens.

Interest areas >

- New clinical biomarkers with high diagnostics potential, apt to be detected through the use of high sensitivity immunoassays. OEM immunoassay opportunities.

Contact >	TEL 938 609 000 www.biokit.com	Pau Planas pau.planas@biokit.com
---------------------	-----------------------------------	-------------------------------------

A1. Who is who?

Company Members



BIOMARIN EUROPE LTD - Sucursal en España

- Mission >** BioMarin seeks to develop product candidates that: Address currently unmet medical needs. Suggest a clear-cut development profile. Provide an opportunity to be first-to-market.
- Products >** Naglazyme. Aldurazyme. Kuvan
- Interest areas >** Metabolic Diseases. Enzyme Replacement Therapies
- Contact >** TEL: 800 808 508
www.bmrn.com
- Felis Iglesias
figlesias@bmrn.com



BIOMASLINIC, S.L.

- Mission >** Manufacture and supplier, acknowledgement and applications of Maslinic Acid and Hidroxitirosol.
- Products >** Animal growth promoter, nutraceuticals, functional foods and antiinflammatory indications.
- Interest areas >** Maslinic acid has demonstrated a high selective apoptotic capacity over tumoral cells, based in the description of its route of activity. The experiments in vivo have been developed having a great success. Now Biomasic S.L. is working about its potential pharmaceutical application. So collaboration is needed to carry on different studies along the different phases of investigation, and also alliances to advance its development and marketing.
- Contact >** TEL: 958 750 981
- José Prados Osuna
biomaslinic@biomaslinic.es



BIOMEDAL, S.L.

- Mission >** To develop new, innovating technologies for the progress of post- genomic research and the efficient industrial production of new biomolecules that are useful for society.
- Products >** Genetic engineering tools for cloning, expression and purification of recombinant proteins and their related products.
- Services >** The design of specialised strains, production of recombinant proteins, sequencing, DNA synthesis, DNA analysis, consultancy and technology transfer.
- Interest areas >** Expression and purification of recombinant proteins, protein analysis, molecular diagnostics, proteomics, etc.
- Contact >** TEL: 954 081 276
www.biomedal.com
- Ángel Cebolla Ramírez
acebolla@biomedal.com



Who is who?



BIOMOL-INFORMATICS

- Mission >** BIOMOL-INFORMATICS offers consulting services on Bioinformatics in areas of research, diagnostics and pharmaceutical industry. Located in the campus of the Autonomous University of Madrid, the company is specialist in Rational Drug Design using 3D computational simulation, Molecular Dynamics of macromolecules and Data Analysis of "Next-Generation DNA Sequencing (NGS)".
- Services >** "In silico" analysis and prediction of new drugs activity on 3D models of proteins and in molecular dynamics techniques applied to docking of compounds. Data Analysis of "Next-Generation DNA Sequencing (NGS)": human genome, cancer-related mutations, hereditary illnesses
- Interest areas >** "In silico" design of anti-obesity drugs. Molecular dynamics simulation of polymerization and depolymerization processes of bacterial septum protein FtsZ: "in silico" design of antimicrobials. Collaborative project 7FP - EU. Data Analysis of "Next-Generation DNA Sequencing (NGS)".
- Contact >** TEL: 647 504 634
www.biomol-informatics.com
- Dr. Paulino Gómez-Puertas
bioinfo@bioinfo.es



BIONATURIS (Bioorganic Research and Services, S.L.)

- Mission >** BIONATURIS is a specialty biopharmaceutical company that develops and manufactures a new generation of more affordable biopharmaceutical products. It makes profitable "unprofitable" market niches being the perfect partner for Global Health or Rare Disease initiatives. Recombinant protein based therapeutics, second generation vaccines and biosimilars.
- Products >** Bionaturis is focused on clinical-stage developing of highly cost-effective biological APIs for orphan diseases. It also develops in-vitro diagnostic kits based on its pool of recombinant products expressed.
- Services >** Bionaturis acts as CDMO developing and manufacturing biological APIs by means of its FLYLIFE technology, in compliance with cGMP standards.
- Interest areas >** In order to implement its business regional strategy abroad, bionaturis is actively looking for local partners within its target markets to reach out-licensing agreements of its FLYLIFE technology as well as codevelopment deals of its lead products.
- Contact >** TEL: 956 547 346
www.bionaturis.com
- Victor Infante (CEO)
victor.infante@bionaturis.com

A1. Who is who?

Company Members



BIONET INGENIERÍA

- Mission >** To provide engineering services and turnkey construction of process package units for the biotech industry (fermentation, downstream, purification, isolation...). Our commitment to our clients means that we offer an integrated service for the whole project life cycle; from lab to industrial facilities and process start up.
- Products >** Lab to Market Engineering [L2M]. From process development at lab-scale we offer: Feasibility studies. Industrialization and scale-up studies. Turnkey construction of pilot plants. Pilot plant testing. Project management of biotech investments: Basic and detailed engineering. Project management or turnkey construction of industrial facilities. Commissioning and start up according to GMPs.
- Interest areas >** Technology centres and R&D departments with new processes that want to add value to the Process Technology Package through a viability study, from an engineering point of view, considering existing / potential investors. New industrial investment projects and facilities that want to introduce a new process / product or that simply want to revamp an existing one. Technology centres that can collaborate in process optimization and troubleshooting.

Contact > TEL: 902 170 704
www.bionet.com

Enrique López
enrique.lopez@bionet.com



BIONOSTRA GRUPO

- Mission >** Group of biotech companies: Bionsotra, Bioalma, Chimera and Microbionta
- Products >** Bionostra: R + D of vaccines of new generation and biotech services in animal health, human health and agrifood area. Bioalma: bioinformatics solutions. Microbionta: investigation of therapeutic antibodies for the human health
- Services >** Detection and quantification of GMOs in foods. Identification and authentication of species. Genotyping. Marker selection

Contact > TEL: 918 060 068
www.bionostra.com

Ana Carmen Martín
anac@bionostra.com





BIOORGANIC RESEARCH AND SERVICES S.L. (BIONATURIS)

- Mission >** BIONATURIS is a specialty biopharmaceutical company that develops and manufactures a new generation of more affordable biopharmaceutical products. It makes profitable "unprofitable" market niches being the perfect partner for Global Health or Rare Disease initiatives. Recombinant protein based therapeutics, second generation vaccines and biosimilars.
- Products >** Bionaturis is focused on clinical-stage developing of highly cost-effective biological APIs for orphan diseases. It also develops in-vitro diagnostic kits based on its pool of recombinant products expressed.
- Services >** Bionaturis acts as CDMO developing and manufacturing biological APIs by means of its FLYLIFE technology, in compliance with cGMP standards.
- Interest areas >** In order to implement its business regional strategy abroad, bionaturis is actively looking for local partners within its target markets to reach out-licensing agreements of its FLYLIFE technology as well as codevelopment deals of its lead products.
- | | | |
|---------------------|---------------------------------------|--|
| Contact > | TEL: 918 060 068
www.bionostra.com | Rocio Arroyo Arranz
rarroyo@bionostra.com |
|---------------------|---------------------------------------|--|



BIOPOLIS, S.L.

- Mission >** The main mission of Biopolis S.L. is to design, produce and purify microorganisms (bacteria, yeasts and filamentous fungi), microbial metabolites: high-value by-products (enzymes, proteins and nucleic acids) following classical fermentation methods and metabolic engineering design.
- Products >** Probiotic against H. pylori infection, Probiotic against rotavirae infection, Use of C. elegans for Alzheimer Candidate screening, Use of C. elegans for obesity testing; Custom design and selection of microbial strains/valuable biochemical compounds, Process design, development and production of microorganisms and derivatives, production of new generation biofuels and biopolymers.
- Interest areas >** Biopolis S.L. offers its services both to industries, such as the food and feed sector, agrochemical, chemistry, pharmaceutical and environment, as well as to public and private research centers.
- | | | |
|---------------------|-------------------------------------|--|
| Contact > | TEL: 963 160 299
www.biopolis.es | Dr. Carlos Malpica
carlos.malpica@biopolis.es |
|---------------------|-------------------------------------|--|

A1. Who is who?

Company Members



BIOSERENTIA BIOTECH ACCELERATOR

- Mission >** Partner with companies, entrepreneurs, investors, governments to create and accelerate Ventures in Life Sciences.
- Services >** Corporate Strategy, Strategic Investments in Life Sciences. R&D Strategy and Management. Fund Raising. BioEntrepreneurship Platform. BioBusiness Incubation & Acceleration. Interim Management. Commercial, Sales & Operational Support.
- Interest areas >** HEALTH: Oncology, Rheumatoid Arthritis, Wound Healing, Transplantation, Cellular Therapies, Vaccines, Pharmacogenomics, Nutrigenomics. Personalized Medicine, Convergent Technologies. ENERGY: biomass optimization, biorefineries strategy and mplementation.
- Contact >** TEL: 914 311 970
www.bioserentia.com
- Jorge Arenas-Vidal
jarenas@bioserentia.com



BIOT

- Mission >** BIOT is a Biotech Enterprise group focus on innovation and R&D in Microbiology. Goals are achieved from the interaction between different BIOT Companies and Research Groups from Universities, Research Institutes and other Companies as well. BIOT develops reliable solutions, products and methodologies based on microorganisms in the areas of agro-food, enviromental and bioenergy production.
- Products >** Selected strains of high biotechnological interest for different industrial sectors: Probiotics. Biofuel producers: methane, ethanol and biodiesel. Bioplastic producers. Soil and water decontamination. Enzymes and biomolecules from microorganisms of high industrial interest. Genetic constructions for improving microbiological processes.
- Services >** Selection, isolation, quantification and identification of microorganisms using biochemistry and genetics techniques. Genetic Engineering Service of microorganisms. Analysis of microbial communities in terrestrial and aquatic ecosystems. Design and conservation of microbiological resources and culture collections of biotechnological interest. Consulting and advice in the field of Microbiology. Innovation, R&D Project Performing and Management.
- Interest areas >** Renewable energies production. Remainders. Biofuel production. Residual, industrial and urban water purification. Biorremediation. Functional food and nutrition-health. New active biomolecules. Nourishing industry. Security and microbiological control. Projects of I+D+i in cooperation.
- Contact >** TEL: 958 750 618
www.biot.es
- Agustin Lasserrot
direccion@biot.es





BIOTHERAPIX MOLECULAR MEDICINES S.L.U.

Mission > Biotherapix Molecular Medicines S.L.U. is a company belonging to Genetrix Group, which specializes in generating high affinity biological molecules to treat inflammatory diseases. Programmes under way: New generation of anti-inflammatory drugs - specifically chemokine receptor antagonists (Diakinas®). Platform for generating and selecting (screening) human monoclonal antibodies for therapeutic and diagnostic purposes.

Interest areas > Molecular therapy. Protein biology. Protein production and purification systems. Development of therapeutic antibodies. Inflammation. Infectious diseases.

Contact >	TEL: 918 063 089 www.biotherapix.com	Juan Sebastián Ruiz jsruiz@genetrix.es
---------------------	---	---



BIOTOOLS B&M LABS, S.A.

Mission > Research, development and manufacture of recombinant enzymes and other tools for molecular biology. Development of new technologies for molecular diagnostics and biomedical research. Comprehensive, fast, simple, robust, automatable and competitive diagnostic solutions, based on internationally patented proprietary technologies and reagents from the company.

Products > Recombinant enzymes, nucleic acid purification systems and other reagents for molecular biology. Ready-to-use: Molecular diagnostic Kits based on Gelification Technology (one tube-one reaction)

Services > Services for design, stabilization and automation of nucleic acid amplification reactions. Services for the development of comprehensive automatable solutions for molecular diagnostics.

Interest areas >

- Technology transfer: Transfer of Biotools Gelification Technology for the stabilization in a single tube all necessary reagents to perform an amplification reaction. This technology has been licensed to the Brazilian Public Health System, and it has been implemented in Brazilian blood banks for the detection of HIV and HCV among blood donors.

Contact >	TEL: 917 100 074 www.biotools.eu	Carmen Tomás- Verdera Alba ctomas@biotools.eu
---------------------	-------------------------------------	--

A1. Who is who?

Company Members



BOSQUES NATURALES, S.A.

Mission > Promotion and maintenance of fine wood forestry plantations. This activity has a triple function: Sustainability, Productivity and Innovation. Bosques Naturales is a company leading research and development which applies vegetal biotechnology and intensive agronomic techniques to its production processes. Its lines of research in forestry biotechnology are oriented to genetic characterization of vegetal material in order to improve the volume and quality of wood.

Products > Plantations of high economic value trees using selected vegetal material which is reproduced "in vitro". The company has a Vegetal Tissue Growth Unit which provides its own germplasm bank.

Services > Bosques Naturales covers all the growth and maintenance costs of the trees during the twenty or twenty-five years which their productive cycle lasts.

Contact >	TEL: 913 604 200 www.bosquesnaturales.com	Teresa Jiménez teresajimenez@bosquesnaturales.com
---------------------	--	--



BTI (BIOTECHNOLOGY INSTITUTE)

Mission > Research and development of new product, new materials and new processes for biological material obtaining through several technologies some of them related to Regenerative Therapies.

Products > Design and manufacture of dental implants, prosthetic components and surgical instruments, Bioactivatable surface for implantology. Technology development for tissue regeneration using Plasma Rich in Growth Factors (PRGF). Educational material and courses development, and its diffusion. Diagnostic software.

Interest areas > Tissue engineering, bone regeneration, regenerative therapies.

Contact >	TEL: 945 160 652 FAX: 945 158 934 www.bti-implant.es www.prgf.es www.institutoeduardoanitua.com www.prgf.net	Dr. Eduardo Anitua Aldecoa eduardo.anitua@bti-implant.es
---------------------	---	---



CANVAX BIOTECH, S.L.

Mission > The search for antigens for vaccines.

Products > Own technology for the identification of antigens inducing T CD4+ and CD8+ response.

Interest areas > Vaccine sector, model animals for protection against infections.

Contact >	TEL: 957 420 870 www.dominion.es	Elier Paz Rojas e.paz@dominion.es
---------------------	-------------------------------------	--------------------------------------



Who is who?

**CEIFER, S.L.**

Mission > Human fertility study and research.

Products > Assisted reproduction techniques, freezing of human fertility cells.

Contact > TEL: 958 254 112
www.ceifer.com

Juan Pablo Ramírez López
info@ceifer.com

**CELLERIX, S.A.**

Mission > Cellerix aims to become the European leader of cell-based pharmaceutical products for the treatment of autoimmune diseases, the Company has already established a platform of expanded adult stem cells of adult origin and is now focusing on the development of an allogeneic platform of eASCs, comprising programs that contemplate local, intravenous and intranodal administration.

Products > Allogeneic Programs: Cx601*. First indication: Complex fistula in Crohn's patient. Phase I/IIa. Cx611: First indication: Rheumatoid Arthritis. Preparing clinical trial application. Cx621. In preclinical status. Cx501* is a cell therapy product for treating epidermolysis bullosa (EB), currently in a phase II clinical trial. Cx501 & Cx601 have been designated an Orphan Drug by the European Medicines Agency EMEA.

Interest areas > With these products, Cellerix aims to tap into much larger markets within the inflammatory and autoimmune disease areas and thereby fulfill its vision of becoming a leader in the cell therapy space and offer patients novel cell-based treatments for unmet medical conditions.

Contact > TEL: 918 049 264
www.cellerix.com

Claudia Jimenez
cjimenez@cellerix.com

**CHIMERA PHARMA**

Mission > Development of immunotherapeutic vaccines against major indications in human health (infectious disease, cancer y cardiovascular)

Products > Universal influenza vaccine – Preclinical. Therapeutic cervical cancer vaccine – Preclinical. Lung cancer vaccine - R&D. Cardiovascular vaccine - R&D.

Interest areas > Looking to establish collaboration with companies and research institutions with extracellular (cell bound or soluble) therapeutic targets relevant to human disease and susceptible to immunotherapeutic approaches.

Contact > TEL: 911 417 150
www.chimera-pharma.com

Arcadio García de Castro
agarcia@bionostra.com

A1. Who is who?

Company Members



CLAVE MAYOR, S.A., S.G.E.C.R.

Mission > CLAVE MAYOR, SA, S.G.E.C.R. is a Venture Capital Entities Management Company. Clave Mayor's aim is to invest in key projects with proven capacity for growth and expansion, which have solid management teams.

Products > Clave Mayor, using funds that it manages, has realized investment in biotechnology companies such as Lactest, Idifarma, Emysalud, Vivotecnía Research Laboratories Ojerpharma, Vivia Biotech, Biomedical Developments Clavesuan and Bionostra. Clave Mayor is interested in evaluating investment opportunities in the health sciences and food industry fields, where it has vast experience.

Interest areas > Projects in consolidated phases with solid proof of concept. Projects managed by solvent and involved teams. Co-investment with other specialized funds. Development projects build-up and growth through acquisitions.

Contact > TEL: 948 203 960
www.clavemayor.com

Ricardo Pérez
perez@clavemayor.com



CLEAN BIOTEC

Mission > Find solutions to resolve environmental pollution problems using clean, sustainable and economical technologies. Improve the natural regulation capacity of ecosystems to reduce environmental impacts. New ways of natural and controlled systems for waste elimination and recycling.

Products > Ecodiagnosics. Environmental audit reports. Waste assesment projects. Paleobotanic studies. Implantation and control of biomonitoring networks. Phytoremediation and Bioremediation. R & D biorremediation projects. Restoration of degraded lands. Reseach and improvement of new phyto and bioremediators. Microorganism research from extreme environments to use in bioremediation and other biotechnological applications.

Interest areas > • Environmental microbiology. Bioremediation. Biomonitoring. Metagenomics.

Contact > TEL / FAX: 941 238 261
www.clean-biotec.com

Nathalie Beaucourt
clean@clean-biotec.com



CPQ INGENIEROS S.L.

Mission > CPQPharma division's prime objective is to provide highly professional consultancy, process and detail engineering and supervision services for the industrial projects of pharmaceutical and biopharmaceutical companies.

Services > Basic and detail engineering and supervision for pharmaceutical and biopharmaceutical companies. Pilot Plant design. Process and bioprocess scale-up. Cost Estimation of biopharmaceutical facilities.

Interest areas > Pharmaceutical and Biopharmaceutical Industrial installations. Cost Estimation of Biopharmaceutical Industrial Installations. Pilot Plant Design. Process and Bioprocess Scale-Up. Industrial Biotechnology. Industrial Nanotechnology .

Contact > TEL: 932 478 830
www.cpqingenieros.com

Ricard Gené
rgene@cpqingenieros.com



Who is who?



DIGNA BIOTECH, S.L.

Mission > To give value to the research undertaken in the CIMA (University of Navarre Applied Medical Research Centre) by means of preclinical and clinical development of the intellectual property generated by the researchers there.

Products > ANTIFIBROTICS: P144 (Schlerodermia, Actinic keratosis, Skin Cancer, ect&) License to ISDIN. P17 (Bone Metastasis, Macular Degeneration). ANTIVIRAL: INFa5 (hepatitis C). STIMULANTS FOR HEPATIC REGENERATION: Cardiotrofina (Hepatic resection, Hepatic transplant, Kidney transplant). IMMUNOMODULATORS: MTA (Multiple Sclerosis), EDA (vaccine adjuvant). GENE THERAPY: Vector Porphyria (Porphyria) License to AMT, Vector IGF-1 (cirrosis) License to AMT.

Contact > TEL: 911 852 510
www.dignabiotech.com

Maite Soria
msoria@dignabiotech.com



DIOMUNE

Mission > Diomune S.L is a biotechnology company with the following aims: Research, development and marketing of new treatments, products and immunology services oriented to human and animal health areas in infectious, inflammatory and autoimmune diseases.

Products > Our main business areas are: developing a drug to cure Canine Leishmaniosis, Research and Development on drugs for the treatment of human septicaemia, and the establishment of license agreements with other companies to use our products as vaccine adjuvants.

Interest areas > Our major interest in collaboration is Vaccine Development. Diomune has a potential immunomodulator able to direct immune responses to be used as vaccine adjuvant. We are looking forward to find partners interested in using them as adjuvant in their vaccines or as immunomodulator in Immune-based diseases.

Contact > TEL: 913 459 214
www.diomune.com

Carolina Egea
cegea@diomune.com

A1. Who is who?

Company Members



ENTRECHEM, S.L.

- Mission >** Our objective is the discovery and development of bioactive new chemical entities (NCEs) from microbial natural products. We generate novel analogs by combinatorial biosynthesis of the corresponding metabolic pathways, identify the most promising candidates and advanced the preclinical development until demonstration of efficacy "in vivo".
- Products >** EntreChem offers genetic engineering for identification and manipulation of metabolic pathways from bacterial natural products of interest in the pharmaceutical (antibiotics, antitumorals, antifungals) and agro (insecticides, herbicides) sectors. EntreChem offers enantiopure products for medicinal chemistry and services of applied biocatalysis, as well as custom synthesis of optically pure compounds.
- Interest areas >** Discovery and development of new drugs from natural products by genetic engineering and biocatalysis. Antitumor and antitumor activity assays (cellular and biochemical), target identification. Early preclinical "in vivo" studies (efficacy, PK). Bioprocess scale-up.
- Contact >**
- | | |
|---------------------------------------|---------------------------------------|
| TEL: 985 259 021
www.entrechem.com | Francisco Moris
info@entrechem.com |
|---------------------------------------|---------------------------------------|



ERA BIOTECH

- Contact >**
- | | |
|--|--|
| TEL: 934 034 773
www.erabiotech.com | François Arcand
info@erabiotech.com |
|--|--|



ERA7 INFORMATION TECHNOLOGIES, S.L.

- Mission >** To help biotech companies and organizations in the biomedical field to take advantage of Information Technologies for a better information and knowledge management. With this objective in mind we design and provide advanced software solutions specially based on Internet technologies.
- Products >** Palinsight Pro: software for DNA palindromicity analysis and representation. Liv-era7: Software specially designed to manage and held real time virtual Congresses and workshops.
- Services >** Services of Knowledge Expression. Services of custom software development of Web applications, intranets, Web platforms and bioinformatics workflows automation. Bioinformatics and biosciences consultancy services.
- Interest areas >** Bioinformatics software development. Participation in R&D and innovation projects including participation in the EU VII Framework Program. Agreements for marketing and distribution of our services and products.
- Contact >**
- | | |
|----------------------------------|--|
| TEL: 958 750 629
www.era7.com | Eduardo Pareja
(Director General)
epareja@era7.com |
|----------------------------------|--|



Who is who?



ESMEDAGRO, S.L.

- Mission >**
- Advising companies in the agrifood and environmental sectors that wish to improve their competitiveness through active participation in European R & D, individual and cooperative, national or international. We offer a comprehensive service in project management from our 5 branches in Spain and Portugal.
- Services >**
- Consulting and Training in R & D.
 - Feasibility studies for projects.
 - Search for funding and partners for projects.
 - Processing and justification of the regional, national and international aids.
 - Development of Preliminary, Technical and Justification Reports.
 - Coordination, Management and Monitoring of R & D projects. Field Trials.
- Interest areas >**
- Companies interested in contacting a consultancy to the presentation of projects in national or international cooperation.
 - Companies seeking involvement of some Spanish agri-food company in one of its projects, since we have a wide portfolio of clients to put in touch with.
 - Platforms or agro-technology networks.
- Contact >**
- | | |
|---------------------------------------|---|
| TEL: 902 104 595
www.esmedagro.com | Luis Alberto Alonso Beltrán de Heredia
laabh@esmedagro.com |
|---------------------------------------|---|



ESTEVE

- Mission >**
- ESTEVE is a private, fully integrated International Group that pursues innovation and excellence in the pharmaceutical-chemical industry, while maintaining its dedication to the promotion of health for the benefit of society. R&D: ESTEVE invests significantly in R&D, focused in analgesia. Its lead program is a Sigma-1 receptor antagonist for neuropathic pain.
- Products >**
- ESTEVE is a diversified company marketing a wide range of ethical and OTC pharmaceutical products, vaccines, generics, products for veterinary use and it manufactures APIs. ESTEVE has also established strategic alliances, ISDIN for dermatological products and ESTEVE-TEIJIN-HEALTHCARE in home respiratory therapy.
- Interest areas >**
- ESTEVE is open to evaluating new opportunities for collaboration, especially in the area of analgesia.
- Contact >**
- | | |
|------------------------------------|--|
| TEL: 934 466 000
www.esteve.com | Dr. Eduard Valentí
evalenti@esteve.es |
|------------------------------------|--|



EUROGALENUS Executive Search

- Mission >**
- Contribute to the identification and development of the best executives in the Biotechnology field.
- Services >**
- Since 1992, recruitment of Board positions, non-executive Directors and senior Scientists. Experience in Biotechnology, Diagnostics, Devices, Electromedicine, Pharmaceuticals, Nutrition, Cosmetics, Veterinary, and their Service companies.
- Interest areas >**
- Recruitment, training, HR consultancy.
- Contact >**
- | | |
|---|--|
| TEL: 913 505 556 / 74 14
www.eurogalenus.com | Luis Truchado
informacion@eurogalenus.com |
|---|--|

A1. Who is who?

Company Members



EUROSEMILLAS, S.A.

- Mission >** To be a company of reference in the farming world, committed to agricultural development in the geographical areas where it is present.
- Products >** Select seeds. CottonGrain: cotton grain animal feed. Cotton fibre. Oleaginous oils. Development of licences for various plants: Fruit trees. Strawberry. Citrus fruits. Raspberry. Others: avocado pears, asparagus, etc.
- Services >** Farming news portal <http://terraagraria.es>. Development of an electronic commerce platform.
- Interest areas >** Select seeds. Genetic improvement. Biotechnology. Development of plant varieties. Farming portal. Extraction of vegetable oils and cotton fibre.

Contact > TEL: 957 421 732
www.eurosemillas.com

José Pellicer
eurosemillas@eurosemillas.com



FARM BIOCONTROL, S.L.

- Mission >** Farm Biocontrol offers complete services of consultancy, assistance and implementation of integral plans in order to reach a biosanitary control in livestock farms. Our mission is provided with the highest biosafety level to pig, cattle, poultry and fish farms.
- Products >** Expert Consultancy and elaboration of reports and Action Plans. Systems to the slurry treatment. Systems to the gas emission reduction. Pest Control. Waters and Effluents Control. Salmonella Control. Laboratory Analysis. Training for technicians, managers and staff. Hazard Identification and Analysis of Critical Control Points.
- Interest areas >** Biotechnology. Biosafety and hygiene. Food traceability. Agriculture. Farms disinfection. Water treatment. Food Industry. Fish farms.

Contact > TEL: 976 660 114
www.farmbiocontrol.com

Rafael Arlegui
internacional@farmbiocontrol.com
r.arlegui@farmbiocontrol.com



FINA BIOTECH, S.L.

- Mission >** The search for kits for diagnosis, prognosis and/ or response to cancer treatment, to cardiovascular and neurodegenerative diseases and others. Therapy with adult stem cells. Licence or sale of products resulting from research to interested companies.
- Products >** HALOSPERM ®, a kit for the diagnosis of male fertility based on DNA fragmentation. F12 ®, kit for genetic risk of thrombosis.

Contact > TEL: 917 991 564
www.finabiotech.es


José-Cándido Arochena Amestoy
Jc_arochena@finabiotech.es





GENDIAG

- Mission >** GENDIAG is a research-driven biotech which aims to facilitate the personalized medicine by offering to the society new genetic diagnostic tools and new therapeutic targets, which can help to the development of innovative drugs, in a worldwide commercialization basis.
- Products >**
- Gendiag's current development status of the projects:
 - CardioinCode®, DNA-Chip - cardiovascular risk. Sudd inCode®, DNA-Chip will determine the risk to suffer sudden death. Trombo inCode® DNA-Chip for genotyping polymorphisms in genes involved in hereditary thrombophilia. Hemato inCode® DNA-Chip will determine the progression of chronic lymphocytic leukemia and assists in treatment selection.
- Interest areas >** GENDIAG creates alliances with investigators, research institutes, biotech and or pharmaceutical companies for the development of their project on a faster and efficient manner. GENDIAG wants to involucrate to the investigator in the development of the project and to share with him the benefits of the marketing when the idea turn into product.
- Contact >**
- | | |
|-------------------------------------|--|
| TEL: 935 093 233
www.gendiag.com | Margarita Garrido
margarita.garrido@gendiag.com |
|-------------------------------------|--|



GENDIAG

- Mission >** Genetadi Biotech is a company that develops new human genetic diagnosis kits specialized in the gynecology, pediatric and oncology biomedical sectors. Our company is integrating its projects of research and development in Systems Biology applying the most modern techniques developed after human genome sequencing.
- Products >** AMNIOCHIP & NEONATAL-ONE
- Services >** Prenatal and neonatal testing by aCGH microarrays. Cytogenetic and molecular genetics services. Analytical metabolic services by mass spectrometry (MS/MS). Human genomic NGS services
- Interest areas >** Nanodiagnosics
Single-molecule DNA sequencing
Human genomic analysis (Bioinformatics)
- Contact >**
- | | |
|--------------------------------------|--|
| TEL: 944 044 343
www.genetadi.com | José Luis Castrillo
info@genetadi.com |
|--------------------------------------|--|

A1. Who is who?

Company Members



GENETRIX, S.L.

- Mission >** Genetrix, created to promote entrepreneurial leaders in the biotechnology sector, is a group of companies aimed at generating value from using the results of academic and clinical research for the benefit of society.
- Services >** Genetrix is constantly working to bring together the outcomes arising from different scientific disciplines, by setting up and maintaining collaborations of a varied nature with public research centres, technological centres, public and private hospitals and pharmaceutical and biotech enterprises. This collaborative spirit is one of the features that most identifies the Genetrix Group's and its has proven to be of great value in making this ambitious business project a reality. The Group is working on the creation of biotech initiatives assessing, designing and executing business plans in the life sciences field.
- Interest areas >**
- Biotechnology
 - Life Sciences
 - Scientific applications for medical purposes
 - Investment in biotechnology
- Contact >**
- | | |
|-------------------------------------|---|
| TEL: 918 063 089
www.genetrix.es | Juan Sebastián Ruiz
jsruiz@genetrix.es |
|-------------------------------------|---|



GENOLAB, S.L.

- Mission >** Genolab is a company dedicated to genetics, especially to the sequencing of human DNA with the aim of offering a preventive and personalized medicine. It combines his activity as laboratory of genetics with the creation of an Internet platform through which there will develop a community of active users on the basis of their genetic profiles.
- Services >** Genolab offers a personalized report of risks associated to more than 70 pathologies. This information is shown in 5 modules: General performance, combining aerobic potential and cardiac affection. Cancerous processes associated with lung and / or heart. Estimation of cardiovascular general risk. General combined performance, physical and mental ("wellness"). Risk of loss of mental capacity
- Interest areas >**
- Internationalization
 - Financing
 - Public and Private Universities
 - Associations of patients
- Contact >**
- | | |
|-------------------------------------|--|
| TEL: 902 030 962
www.genolab.com | José E. Olivares
finanzas@genolab.com |
|-------------------------------------|--|





GENÓMICA, S.A.U.

- Mission >** To offer experience and quality in all its products and services. To provide the health system with a tool for differential clinical molecular diagnosis applicable to infectious and oncogenic diseases. To be a reference centre in Spain for genetic identification tests, working under an accreditation frame provided by ENAC.
- Products >** Molecular diagnostic kits focused on infectious and oncogenic diseases.
- Services >** Human DNA identification tests. Forensic Genetics technology transfer by -Turn key projects-: design, assembling of the laboratory, training of personnel, technical service and population database creation. Using genomics and proteomics tools, systems are being prepared to detect therapeutic activity in marine organisms for different diseases.
- Interest areas >**
- In licensing: Oncology molecular diagnostic systems. New molecular diagnostic technologies.
 - Out licensing: Technology transfer and training in forensic genetics.
- Contact >**
- | | |
|-------------------------------------|---|
| TEL: 916 748 990
www.genomica.es | Rosario Cospedal
rcospedal@genomica.es |
|-------------------------------------|---|



GENZYME, S.L.

- Mission >** The discovery and development of innovating products and services for serious pathologies, with special attention to rare diseases. Genzyme S.L. is a subsidiary of Genzyme Corporation through Genzyme BV in Naarden (The Netherlands), dedicated to the development and introduction of therapeutic solutions for unresolved medical problems.
- Products >** Lysosomal Storage Diseases: Gaucher, Fabry, Hurler and Pompe diseases. Hyperphosphatemia in chronic renal disease. Oncohematology. Articular Viscosupplementation. Prevention of surgical adhesions. Biomaterials. Immunological disorders. Neurodegenerative diseases. Cellular therapies.
- Interest areas >** Rare diseases/Orphan drugs. Renal disease. Oncology / Transplant
- Contact >**
- | | |
|-------------------------------------|---|
| TEL: 916 591 670
www.genzyme.com | Fernando Royo
genzymespain@genzyme.com |
|-------------------------------------|---|



GILEAD SCIENCES, S.L.

- Mission >** Investigate, Develop and commercialize innovative drugs in therapeutics areas with uncover needs, with the objective to improve curation and surveillance rates in patients with severe infectious diseases.
- Products >** HIV :VIREAD(Tenofovir disoproxil). EMTRIVA(Emtricitabina). TRUVADA(Tenofovir disoproxil y emtricitabina en un solo comprimido). ATRIPLA(Tenofovir disoproxil, emtricitabina & efavirenz ,one pill, once a day) HEPATITIS B :HEPSERA (Adefovir dipivoxil), VIREAD (Tenofovir disoproxil) ANTIFUNGAL : AMBISOME(Anfotericina B liposomica)
- Contact >**
- | | |
|------------------------------------|---|
| TEL: 913 789 830
www.gilead.com | Roberto Urbez Plasencia
roberto.urbez@gilead.com |
|------------------------------------|---|

A1. Who is who?

Company Members



GP-PHARM, S.A.(Grupo Lipotec)

- Mission >** Research, development, manufacture and commercialization of Injectable products for the areas of Oncology, Nervous Central System, Cardiology and Urology. Based on two Drug Delivery Technological Platforms (Micro- nanspheres and Liposomes)
- Products >**
- Development and Contract Manufacturing services based on the two Drug Delivery Platforms of injectable drugs (Micro- Nanspheres and Liposomes).
 - Products in phase of commercialization or register (Octeotride-Irinotecan-Leuprolide-Oxaliplatin-Gemcitabina). RD Projects in different phases of development (Oncology-CNS-Cardiovascular)
- Interest areas >**
- Utilization of our Delivery Systems for development new molecules or for improvement of current molecules that already have lost patent. Alliances with pharmaceutical companies to take our products to the Market (USA, Japan, China, India).
 - Alliances with pharmaceutical companies to do joint development of GP-Pharm's projects. Manufacture and Development for pharmaceutical companies in our Laboratories and Manufacturing Plant.
- Contact >**
- | | |
|--------------------------------------|-------------------------------------|
| TEL: 936 388 000
www.gp-pharm.com | Isabel Bazán
ibazan@gp-pharm.com |
|--------------------------------------|-------------------------------------|



GRIFOLS ENGINEERING S.A.

- Mission >** The company belongs to the Grifols holding and is specialized in engineering and consultancy services for the biotechnological and pharmaceutical fields. Grifols Engineering's objective is to become the appropriate collaborator for the scale-up of the biotech field companies, from development phases to industrial production.
- Products >** Services of Biopharmaceutical Engineering and Consultancy. Machinery for biotechnological process: Fermentation, purification and aseptic filling. Prototypes of machinery for biotechnological processes.
- Interest areas >**
- Biotechnology. Technological applications for medical purposes.
- Contact >**
- | | |
|--|--|
| TEL: 935 710 393
www.grifolsengineering.com | Oriol Argemi
oriol.argemi@grifols.com |
|--|--|



Who is who?



GRUPO FARMASIERRA

- Mission >** Pharmaceutical group of companies specialised in Research & Development, Manufacturing, Distribution and Marketing of Medicines, Food Supplements and Cosmetics operating at national and international level
- Products >** Gynaecology: Remifemin, Femiplante, Carbocal, Tricolam, Flucosil gel. Paediatrics: Calcio 20, Aminoveinte, Trofalgón, Trilombrin, Ibuprofeno. Urology: Prosturo. Generics: Acetilcisteina, Bisoprolol Farmasierra, Tramadol Farmasierra. Pain & Inflammation: Ibuprofeno Farmasierra, Tacrón, Astefor, Ibustick. Central Nervous System: Sinequan. Metabolism: Diabinese. Anti-infectives: Terramicina, Terra-Cortril, Fungo Farmasierra. Línea 20: Ferro 20, Sol 20, Derma 20, Multivitamínico Farmasierra. Food Supplements: Bifibran, Lactospore, Omega 3, Visdon, Omega 6, Resvecor, Nutrobal, Aceite de Onagra. Cosmetics
- Interest areas >** Technological Development and High Tech Contract Manufacturing Services. Research & Development. Manufacturing of investigational Medicinal Products (IMP). Licences out. Licences in. Warehousing and Distribution Contract Services
- Contact >** TEL: 916 570 659
www.farmasierra.com
- Tomás Olleros
tomas@farmasierra.com



GRUPO P-VALUE

- Mission >** Support biotechnology companies with their research and development programs, involved in the starting up and development of clinical research investigations through our technical and human means.
- Services >** We are a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, due to our wide experience in Clinical Research. We specialise in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies, depending on the needs of our clients.
- Interest areas >** We are interested on collaborating on research and development projects with innovative medicines, or any other clinical research for all therapeutic areas.
- Contact >** TEL: 902 012 292
www.grupop-value.com
- Francisco Javier Navarro
javiernavarro@grupop-value.com

A1. Who is who?

Company Members



HISTOCELL, S.L.

- Mission >** HistoCell works in Tissue Engineering and Cell Therapy to develop innovative products for regenerative medicine. HistoCell facilities include a 65m2 GMP certified production facility for cell therapy medicinal products, and several laboratories for quality control and R&D. HistoCell works with differentiated adult stem cells obtained from adipose tissue
- Services >** Cell Therapy medicaments. Divided in three main lines: GMP production of adult and mesenchymal stem cells. Development of new cell therapy medicaments
Development of biomaterials for regenerative medicine
- Interest areas >** HistoCell works on new research lines to answer to possible lacks existing in other regenerative medicine areas. Our company will also provide new cell therapy products and new biomaterials for regenerative medicine. HistoCell is interested in alliances with companies or research groups specialised in developing new biomaterials for tissue engineering.
- Contact >** TEL: 946 567 900
www.histoCell.com
- Julio Font
info@histocell.com



IDEN BIOTECHNOLOGY S.L.

- Mission >** Iden Biotechnology is a company with scientific profile whose main activity is the generation, development and exploitation of biotechnological knowledge. Iden Biotechnology is a technology transfer company matching market demands with biotechnology research interests from universities and technology centers.
- Products >** Iden Biotechnology develops biotechnological patents as its main product. The company also offers additional services as sub-contracted research projects, technical and financial project management, several biochemical analysis and Technology-Based Innovative Enterprises (EIBTs) creation advising.
- Interest areas >** Present and future areas of interest for Iden Biotechnology include the development of new raw materials suitable for biofuels industry, biomaterials industry, as well as molecules with industrial, pharmaceutical, agricultural and nutritional value.
- Contact >** TEL: 948 152 122
www.idenbiotechnology.com
- Nora Alonso
Nora.alonso@idenbiotechnology.com



IGEN BIOTECH, S.L.

- Mission >** IGen Biotech is a privately-owned firm focused on getting practical applications from advances made in medical research, turning them into products and leading them to the market. Company scope is focused on biomedicine, including new diagnostic kits for different diseases, pharmaceutical products and other therapies. Igen is currently developing agreements with other private firms and with public and private research centres to collaborate with them to jointly develop new R&D projects.
- Products >** Diagnostic kits.
- Contact >** TEL: 915 102 999
www.igenbiotech.com
- David Segarra
d.segarra@igenbiotech.com



Who is who?

**IMEGEN**

- Mission >** Development of diagnostic tests based on genetic and genomic analysis, focused on the detection of hereditary disorders. Design and production of sets of analysis based on molecular biology techniques, for the diagnosis of human diseases. Promotion of alliances and collaborations public private.
- Services >** Services of molecular diagnostic. Sets of molecular analysis of human pathologies. Research Projects in genomic.
- Interest areas >** Diseases of hereditary transmission. Oncology. Farmacogenomics. Next generation sequencing.
- Contact >** TELF: 963 212 340
www.imegen.es

Ana Martínez Hortigüela
anam.hortiguela@imegen.es

**IMMUNOSTEP, S. L**

- Mission >** IMMUNOSTEP is working day by day to achieve high quality products and services, to offer a new and proactive view to the search for solutions to the problem of cancer, producing reagents employed in diagnosis and research.
- Products >** IMMUNOSTEP, S. L. has two divisions: Development, production and marketing tool for diagnosis of blood diseases by flow cytometry, IMMUNOSTEP Diagnostics. Development, production and marketing tool for research as well as providing services, IMMUNOSTEP Research.
- Interest areas >** In vitro and molecular diagnostics, Biotherapy
- Contact >** TEL: 923 294 827
www.immunostep.com

D. Ricardo Jara
rjara@immunostep.com

**INMUNOLOGÍA Y GENÉTICA APLICADA, S.A. (INGENASA)**

- Mission >** Research, development, production and commercialisation of biotech products for animal health care.
- Products >** Serologic diagnosis assays. Molecular diagnosis assays. Second generation vaccines.
- Services >** Protein expression, monoclonal antibodies.
- Contact >** TEL: 913 680 501
www.ingenasa.es

Carmen Vela Olmo
cvela@ingenasa.es

A1. Who is who?

Company Members



Mission > Ingredientis Biotech is a biotechnology company dedicated to the discovery and development of bioactive ingredients with effects on obesity, cardiovascular disease and diabetes, for functional food industries and dietetics.

Products > Discovery of Active Ingredients. Product Development. Nutrition and Health. Use of Byproduct.

Interest areas > Discovery of bioactive compounds. Nutritional evaluation of bioactive compounds and functional foods. Developing products, processes and technology to food. Membrane separation technologies, microencapsulation, solubilization and controlled release of nutrients and bioactive compounds.

Contact >	TEL: 958 750 985 www.ingredientisbiotech.es	Jesús Jiménez López jesusjimenez@ingredientisbiotech.es
---------------------	--	--



INNOFOOD I+D+i, S.L.

Mission > INNOFOOD I+D+i S.L. is a spin-off create to improve the research and technological development of the food industry through the benefit of services and projects of R&D to the industry and whose application will be as much to ingredients as to food products, obtaining with it the increase of the productiveness and quality, improves of the client competitiveness.

Services > Assays and Improvement of food products shelf life. Design and development of new ingredients and foods. Special product design (functional, nutraceutical&). Conventional products redesign. Improvement of sensorial characteristics and commercialization. Application of new technologies to the elaboration of new foods (production systems, preservation, packaging...). Development of new functional and bio-ingredients from by-products.

Interest areas > We offer the know-how in ingredients and products development and their application in different foods. Collaboration or joint-venture to work together in this field. Functional foods and functional ingredients. Projects about by-products from agrofood industry. Food biotechnology.

Contact >	TEL: 958 750 607 www.innofood-idi.com	Jose Maria Fernandez Gines jmfernandez@innofood-idi.com
---------------------	--	--



Who is who?


INSTITUT UNIV. DE CIÈNCIA I TECNOLOGÍA, S.A. (IUCT)

- Mission >** The mission of IUCT is to make use of its knowledge, expertise and capabilities to generate new technologies, products and processes for its industrial application in the Chemical, Pharmaceutical, Biotechnological and Environmental fields.
- Products >** Drug Discovery. Industrial Biotechnology. Drug Development. Green Chemistry Technology Platforms: Industrial Biotechnology, Sustainable Chemistry, Drug Discovery, High Throughput Analysis, Optimization of the Chemical Processes and Drug Development.
- Services >** Development and Innovation projects under contract (Contract Research). Technological services (Analysis and Consultancy). Transfer of knowledge and specialised training. Organization of seminars, workshops and congresses.
- Interest areas >** Pharmaceutical, biopharmaceutical and cosmetic sector. Chemical industry and fine chemical. Food industry. Environmental/ Health at work.

TEL: 935 793 432
www.iuct.com

Angeles Molina
luct.sales@iuct.com


INSTITUTO BIOMAR, S.A.

- Mission >** Discovery and development of new compounds and process of industrial interest from marine microorganisms.
- Products >** Research and development projects for companies in different industrial sectors. Production and selling of compound from microorganisms (GMP, APIs). Service of Analysis and structure determination of compounds. Service of Microbial Taxonomy. Provider of Cellular Lines, loaded in 96 well plates, for assays.
- Interest areas >** PHARMACEUTICALS: discovery and development of new drugs (Cancer and anti-microbials in-house and other areas with different Partners). FOOD: natural preservatives. AQUACULTURE: microbiological control of infections. AGRICULTURE: microbial biopesticides. ENOLOGY: starters for alcoholic and malolactic fermentations. COSMETIC: antifungi, antioxidants and whiteners. BIOFUEL: production from cyanobacteria and microalgae.

Contact > TEL: 987 84 92 00
913 860 159
www.institutobiomar.com

Dr. Antonio Fernández
ibiomar@institutobiomar.com


INTEGROMICS, S.L.

- Mission >** To provide the market with up to date knowledge on IT solutions in the field of life sciences and particularly in genomics and proteomics.
- Services >** The development and marketing of software for genomic and proteomic data management, analysis and mining. Professional services relating to these products.
- Interest areas >** The development and commercialisation of software for genomics, proteomics and related sectors.

Contact > TEL: 958 750 627
www.integromics.com

Vicente Rodríguez
Vicente.rodriguez@integromics.com

A1. Who is who?

Company Members



INTELLIGENT PHARMA

- Mission >** Intelligent Pharma is a unique and innovative computational solution provider focused on drug design and target validation. Intelligent Pharma develops customized and highly-specialized computational solutions for our clients in order to reduce their costs, time and/or risks in their molecular research projects.
- Products >** In early research stages we offer the following areas of expertise: Computer-aided drug design. Molecular modeling. Virtual screening. Compound library management and intelligent accessory tools. ADME/Tox modeling. Knowledge extraction and data mining from chemical and biologic databases. Biologic image processing. Improved/enhanced supercomputational research infrastructure.
- Interest areas >** Drug discovery
- Contact >** TEL: 934 034 551
www.intelligentpharma.com
- Ignasi Belda
ibelda@intelligentpharma.com



LABGENETICS, S.L.

- Mission >** To carry out highly accurate and decisive genetic tests within a minimum response period. To apply the most advanced techniques to identify alterations in the DNA sequence related to the onset of the most prevalent hereditary diseases in Europe. To consolidate as the Reference Centre in Forensic Genetics and Human Genetic Identification Tests.
- Products >** Forensic Genetics: Paternity testing, parentage (kinship) analysis and genetic identification (DNA fingerprinting) from any biological traces. Clinical Genetics: Molecular Diagnostics of more than 250 hereditary diseases. Technology Transfer: Set up and start up of Molecular Biology -turn-key- laboratories, focused on human genetic analysis. Scientific Advisory Services: Interpretation of expert reports based on DNA evidences in civil legal and penal procedures.
- Interest areas >** Development of new Molecular Diagnostic techniques. Projects of Forensic Genetics and Genetic Diagnostic training. Development and distribution of new Molecular Diagnostic Kits.
- Contact >** TEL: 916 592 298
www.labgenetics.com.es
- Jorge Puente Prieto
jorge.puente@labgenetics.com.es





LABORATORIOS CALIER, S.A.

- Mission >** Research, development and commercialisation of veterinary products aimed at production animals, together with specialised products aimed at pets and a select range for horses.
- Products >** Pharmacological pharmaceutical specialities. Immunological pharmaceutical specialities. Animal care, hygiene and handling products. Biocides. Animal food additives.
- Services >** Autovaccines, diagnostics and eradication programmes. The production of antigens and proteins produced by heterologous systems, in order to obtain products for: Diagnosis, control and prophylaxis. Vaccine products with detectable vaccine antigens. Hormone products for synchronisation of animals coming into heat and ovulation induction.
- Interest areas >** General immunology. Animal reproduction. Expression systems of heterologous recombinant proteins.
- Contact >** TEL: 938 495 133
www.calier.es

Joaquim Tarés
mmorlan@calier.es



LABORATORIOS JUSTE, S.A.Q.F.

- Mission >** JUSTE, S.A.Q.F. is a company which researches, develops and distributes pharmaceutical products. JUSTE also has an outstanding R+D and industrial activity related to the generation and manufacture of soft-gel capsules.
- Products >** The Therapeutics Division commercializes prescription drugs for the three following Areas: Primary Care, Women's Health Care and Central Nervous System. The Hospital Division remains dedicated to the diagnosis within the radiology field. JUSTE has diversified its hospital diagnosis line taking part and acquiring new projects and products which incorporate innovative technologies on diagnosis, oncology and anesthesia.
- Interest areas >** JUSTE maintains a continual interest in collaborating on development projects as well in establishing License agreements (exclusive licenses, co-marketing and/or co-promotion agreements) for Spain, Portugal, Central America and South America countries in the following therapeutic areas Primary Care, Women's Health Care and Central Nervous System and products for diagnosis and treatment aimed at hospitals. JUSTE is aware of the advances in biotechnology and considers very important the use of genetics for a personalized medicine. JUSTE commits itself in the innovative biotechnology industry with new products for clinical diagnosis.
- Contact >** TEL: 917 248 200
www.juste.com

Charo Guinea
roguinea@juste.net

A1. Who is who?

Company Members



LABORATORIOS LETI, S.L.Unipersonal

- Mission >** Laboratorios LETI's objective is to obtain sustainable improvements in health and wellbeing, paying attention to prevention, diagnosis and personal healthcare. Having innovative, patented products is a key part of LETI's objective; for this reason, research is an absolute priority and to which the company devotes over 10% of its turnover.
- Products >** Allergy, Dermatology, Diagnostics, and Vaccines are the company's focus. The Allergy Unit produces allergenic extracts for in vivo diagnosis and treatment. Dermatology develops skincare and other personal healthcare products. Diagnostics provides in-vitro diagnosis, quick tests, and serological tests. Vaccines focuses on the prevention of Leishmaniasis and other Global Health threats.
- Interest areas >** Laboratorios LETI seeks partners interested in R&D collaborations for diagnostics, vaccines, and therapies related to Allergy, Dermatology, Immunology, and Infectious Diseases. Within the area of diagnostics and vaccines, we are particularly interested in innovations affecting global health. In addition to R&D, international expansion is a fundamental element for our company.
- Contact >** TEL: 933 945 350
www.leti.com
- Ellen Caldwell
ecaldwell@leti.com



LABORATORIS SANIFIT, S.L.

- Mission >** Sanifit's work focuses on research and development of innovative drugs and products for the treatment and/or prevention of diseases, mainly in the cardiovascular, renal, osteoporosis and dental fields.
- Products >** SNF-471: experimental drug in preclinical phase indicated for the treatment of cardiovascular calcifications. SNF-472: experimental drug in preclinical phase indicated for the treatment of coronary calcification in end stage renal disease patients. SNF-571: experimental drug in preclinical phase for the treatment of calcic renal lithiasis. SNF-671: experimental drug in preclinical phase for the treatment of osteoporosis. ASB-01: consumer health products for the treatment of dental calculi. Patents granted.
- Interest areas >** Drugs and other products in the following areas: Urology. Cardiology. Dermatology. R+D of new drugs.
- Contact >** TEL: 871 703 062
www.sanifit.com
- Bernat Isern Amengual
laboratoris@sanifit.com



Who is who?



LAIMAT, SCIENTIFIC TECHNICAL SOLUTIONS, S.L.

- Mission >** Applied investigation for the development of new products for the biotechnological, agroalimentary, pharmaceutical and chemical sectors. Contribute to improve society's health and welfare, participating in the development of new products for pharmaceutical and agroalimentary industries, by applied investigation using physico-chemical particles properties Knowledge.
- Services >** Services as external R&D department, for companies from the agroalimentary, pharmaceutical and chemical sectors. Provides solutions to physical chemical problems: Solubility, Stability, Formulation, Microencapsulation. Development of a new analytic technology for determination of toxics and early.
- Interest areas >** R&D Projects, as R&D developers in Health, Nanotechnology and Biotechnology areas: Microencapsulation and controlled delivery of drugs. Solubility. Stability control. New analytic technology for determination of toxics and early diagnosis. Provides: portability, quickness, sensitiveness, selectivity and easy use.
- Contact >** TEL: 958 750 951 / 858 100 141
www.laimat.com
- Josefina Pedradas
fpedrajas@laimat.com



LIPOPHARMA

- Mission >** Lipopharma is a biotech company aimed at the discovery, design and initial clinical development of new medicines aimed to be used in human pathologies over the basis of the Membrane Lipid Therapy (MLT). Our initial objective is to complete Minerva's Phases I and II of clinical trials for Lung Cancer and Glioma.
- Products >** Minerva, the first molecule to be developed, combines a powerful anti cancer effect with an absence of toxicology or side effects. Lipopharma is also developing a portfolio of new products based on the MLT with potential applications in fields such as neurodegenerative diseases, cardiovascular pathologies or cancer.
- Interest areas >** Lipopharma would be interested in collaboration agreements with other companies / research groups specialized in the field of membrane lipid's interactions. Lipopharma will also seek alliances with large multinational pharmaceutical companies who can bring in the technical and financial muscle needed to complete last phases of clinical trials, register and eventually commercialize the products worldwide.
- Contact >** TEL: 971 439 886
www.lipopharma.com
- Vicenç Tur
v.tur@lipopharma.com



LONZA BIOLOGICS PORRIÑO, S.L.

- Mission >** Produce recombinant monoclonal antibodies from mammalian cell culture.
- Products >** Cell culture and recombinant monoclonal antibodies
- Contact >** TEL: 986 344 060
www.lonza.com
- Luis Sánchez Ureña
lonzaporrino@lonza.com

A1. Who is who?

Company Members



LONZA BIOLOGICS PORRIÑO, S.L.

- Mission >** Design, development and commercialization of systems for molecular and immunohistochemical diagnostic in oncology and infectious diseases.
- Products >** Antibodies and detection systems for immunohistochemistry. Kits for molecular analysis of gene rearrangements in lymphomas. Kits for screening and genotyping of human papillomavirus by PCR. Kits for molecular diagnostic of zoonotic bacteria. Kits for mutational analysis of tumoral genes.
- Services >** Molecular diagnostic in infectious pathology. Mutational analysis of genes involved in pharmacogenetic and inherited cancer.
- Contact >** TEL: 958 271 449
www.masterdiagnostica.com
- Juan Jiménez Rodríguez
juan.jimenez@vitroweb.com



MERCK, S.L.

- Mission >** Research and development, production and commercialization of products of high quality in the pharmaceutical and chemical sectors. We focus our activities on businesses where we achieve competitive advantages thanks to the innovation of our products, services and systems. We guarantee that our objectives are fulfilled by developing company policies and practices that are responsible with the society and the environment.
- Products >**
- Pharma: Merck Serono: includes innovative leading prescription drugs, for the treatment of cancer, multiple sclerosis, infertility, growth disorders, cardiovascular and metabolic disorders and psoriasis. Consumer Health Care: includes a wide range of well-known over-the-counter drugs for everyday health.
 - Chemical: Liquid crystals: leading manufacturer for LCD displays. Pigments: effect pigments for the automobile industry, plastics, coating; pigments and other substances for the cosmetic industry. Reagents and test kits: inorganic high quality reagents, organic chemical products, laboratory tests, among others. Life Science Products: Excipients, active principles and other materials for the pharmaceutical and biotech industry.
- Contact >** TEL: +34 935 655 500
www.merck.es
TEL: +34 917 454 400
www.merckserono.net
- Laura González-Molero
comunicacion@merck.es



Who is who?



MERCK, SHARP & DOHME DE ESPAÑA, S.A. (MSD)

- Mission >** Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching programs that donate and deliver our products to the people who need them. MSD
- Products >** MSD pipeline has over 20 promising late-stage candidates spanning the stages of life, and we have a presence in more than 100 countries around the world, including emerging markets. MSD also publishes unbiased health information as a non-profit service.
To visit MSD pipeline: <http://www.merck.com/research/pipeline/home.html?WT.svl=content>
- Interest areas >** Scientific discovery and development have always been the cornerstones of our company. Today, we conduct research in a broad range of therapeutic categories including cardiovascular disease, infectious diseases, vaccines, cancer, neurology and women's health. And, to help achieve our goal of saving and improving lives around the world, we are expanding our capabilities in new areas, such as biologics.
- Contact >** TEL: 913 210 600
www.msd.es Carmen López-Lavid
carmen_lopez_lavid@merck.com



MICROBIONTA

- Mission >** Application of our technologies of expression and selection of recombinant antibodies in bacteria to the development of new therapeutic antibodies.
- Products >** Technological platform for the selection of antibodies in bacteria by bacterial display. Specific antibodies as therapeutic agents for inflammation, cancer and infectious diseases.
- Interest areas >** New targets involved in inflammation, cancer and infectious diseases, for the selection of new antibodies.
- Contact >** TEL: 911 417 150
www.microbionta.com Myriam de Grado
mdegrado@microbionta.com



MILTENYI BIOTEC

- Mission >** Miltenyi Biotec develops, produces, and markets state-of-the-art products and services for cell separation, cell analysis, cell culture, molecular biology, and clinical research applications.
- Products >** MACS® Technology for Cell Separation. AutoMACS™ CliniMACS®. Microarrays & Bioinformatics. Adsorbers for Therapeutic Apheresis.
- Contact >** TEL: 915 121 290
www.miltenyibiotec.com Iván Alvarez-Sierra
macs@miltenyibiotec.es

A1. Who is who?

Company Members



MONSANTO AGRICULTURA ESPAÑA, S.L.

Mission > To attend the world's food needs. To conserve natural resources. To protect the environment. To serve our customers and our shareholders.

Products >

- Monsanto is a group of companies whose activity is aimed at the development and improvement of agriculture and the food sector. For over one hundred years Monsanto has been researching, developing and commercialising services for the farming sector and it has concentrated its aims on providing sustainable agricultural systems, beneficial for farmers all over the world.
- Monsanto is committed to developing safe technologies and products that are beneficial for both farmers and consumers.
- Our most outstanding products are our herbicides from the Roundup range and the Dekalb brand seeds. For further information on our products go to: <http://monsanto.es/monsantoes/productos.html>

Interest areas > Plant Biotechnology. Conservation farming. Biofuels.

Contact > TEL: 913 432 701
www.monsanto.es

Jaime Costa Vilamajó
jaime.costa@monsanto.com



NEOCODEX, S.L.

Mission > NeoCodex's objective is to generate value by discovering and developing pre-products to feed standard production processes for new pharmaceuticals. The company discovers and develops these pre-products up to pre-clinical stage.

Products > DNA biorepository. DNA genotyping and genomic support services. Detailed interpretation of results derived from whole genome scans. Integral research services in genomics. Molecular diagnostic. Patents derived from our research activity.

Interest areas > Neocodex, using genomic approaches, has discovered several drug targets involved in the development of diseases such as Alzheimer's disease, Parkinson's disease, cardiovascular risk and cancer. We are very interested in carrying out proofs of concept on those discoveries in animal models and to perform clinical trials.

Contact > TEL: 955 047 618
FAX: 955 047 325
www.neocodex.com

Rocio Pascual
(Secretaria)
rpascual@neocodex.es





NEURON BioPharma

- Mission >** Neuron BPh Group's aim is to develop biosolutions through its two business divisions: Neuron BioPharma: discovery and evaluation of drugs and nutraceuticals to prevent and treat neurodegenerative diseases. Neuron BioIndustrial: development of bioprocesses for pharmaceutical, chemical, agro-food and biofuel applications.
- Products >** Neuron BioPharma: NST0037; neuroprotective and hypocholesterolemic compound. NST021; neuroprotective compound. NST005; neuroprotective compound. MDF005; neuroprotective compound (nutraceutical). Neuron BioIndustrial: MICROBIOTOOLS ® Biotransformation platform. MicroBioOil ® technology to produce second-generation biodiesel. TriBioPlast ® technology for the development of bioplastics.
- Interest areas >** NEURON BPh is always open to incorporate innovative technologies in the fields of the Neurobiology, Microbial Biotechnology and the Natural Products Chemistry.
- Contact >** TEL: 958 750 598
www.neuronbp.com
- Javier Velasco
info@neuronbp.com



NEUROSCIENCE TECHNOLOGIES, S.L.

- Mission >** Research on the mechanisms of neuropathic pain. Development of new therapeutic drugs.
- Products >** New drugs for neuropathic pain treatment.
- Services >** Studies on patients with neuropathic pain. Studies on experimental models of axonal hyperexcitability.
- Interest areas >** Development of new drugs targeting axonal hyperexcitability. Development of diagnostic devices for neuropathic pain.
- Contact >** TEL: 934 020 164
www.nsc-tec.com
- Dra. Cristina Quiles
cquiles@nsc-tec.com

A1. Who is who?

Company Members



NEWBIOTECHNIC, S.A.

- Mission >** To identify, protect and commercialise microbiological and molecular tools with an immediate, practical application in the farming and agrifoodstuffs sector, which are safer for the consumer and more respectful with the environment. Founded in 1999, NBT is an R&D company in farming and agrifoodstuff biotechnology, with three business areas: 1) Biological control agents 2) Gene technology for improving crops and 3) Molecular diagnostics services.
- Products >** Biological Control Agents (biofungicides, bioinsecticides). Tools for plant improvement by genetic transformation.
- Services >** Genomic and Bio-IT services. Phytopathological diagnostics. Agrifoodstuff diagnostics. Veterinary diagnostics. Human genetic diagnostics.
- Interest areas >** The development of microbiological products for crop protection. Submerged fermentation technology and product recuperation. Co-development/ distribution of natural products for agriculture (microbiological products, plant extracts, organic extracts, etc.). Development of diagnostic genetic tests for farming, aquaculture, veterinary and food product applications. The development of concept tests in plant genetic transformation.
- Contact >**
- | | |
|--|----------------------------|
| TEL: 955 776 710
934 504 899
www.newbiotechnic.com | Manuel Rey
mrey@nbt.com |
|--|----------------------------|



NORAY BIOINFORMATICS, S.L.U.


- Mission >** NorayBio is a bioinformatics company that supports the life sciences sector. Main product lines: AniBio * NorayBanks * NorayLIMS * NorayLIMS OMICS * Fivisoft *
- Products >** With the creation of its products, NorayBio intends to cover work requirements in all aspects of life sciences. Animal research centres. Biobanks. Assisted reproduction and infertility centres. Laboratories and research units. Pharmaceutical industry. Tailored developments for any need in biotechnological research.
- Interest areas >** NorayBio looks for strategic alliances and collaborations to continue with the internationalization of its products and of the company by means of opening new delegations.
- Contact >**
- | | |
|--------------------------------------|----------------------------------|
| TEL: 944 036 998
www.noraybio.com | Marta Acilu
info@noraybio.com |
|--------------------------------------|----------------------------------|





NORAY BIOSCIENCES Group (Noray BG)

- Mission >** Noray BG is a holding group focussed on Biosciences, whose mission is to manage and integrate the companies in the Biosciences sector to enhance their access to the market and their internationalization. NorayBio is currently composed by two companies: Histocell and NorayBio.
- Services >** Noray BG is a holding dedicated to the management of its companies (Noray-Bio and Histocell, at the moment), in different fields like strategic management, business development, internationalization, financial management and human resources.
- Interest areas >** Noray BG's strategy for the near future is based on the continuous growth by means of collaboration agreements with other companies and institutions, development of new innovative products and acquisition or merger with new firms, everything done with the firm idea of motivating the expansion throughout the European and international market.
- Contact >**
- | | |
|-------------------------------------|--------------------------------|
| TEL: 944 036 998
www.noraybg.com | Julio Font
info@noraybg.com |
|-------------------------------------|--------------------------------|



NOSCIRA

- Mission >** To research, develop and commercialise innovative drugs for the treatment and prevention of diseases of the Nervous System with unmet medical needs, especially Alzheimer's disease (AD) and Progressive Supranuclear Palsy (PSP; rare disease).
- Products >**
- Two compounds in clinical development: Nypta® (NP-12), only GSK-3 inhibitor in clinical phase II, for AD and PSP; NP-61, beta-amyloid modulator and acetylcholinesterase inhibitor, currently in clinical phase I.
 - Projects in earlier stages: Neuroprotection (alfa-secretase activators); NP-103 (GSK-3 inhibitor of marine origin); Cell therapy project
- Interest areas >** Noscira is open to the negotiation of license Nypta® (NP-12) and NP-61 for the US and Japan, while maintaining certain rights in Europe. Noscira also contemplates the possibility of establishing specific collaboration agreements aimed at the co-development of any of its lines of research or compounds in the area of nervous system.
- Contact >**
- | | |
|-------------------------------------|---|
| TEL: 918 061 130
www.noscira.com | Belén Sopesén Veramendi
bsopesen@noscira.com |
|-------------------------------------|---|

A1. Who is who?

Company Members



OMNIA MOLECULAR, S.L.

- Mission >** Omnia Molecular Ltd. (Omnia) is a biotech start-up, focused on the development of a new strategy for the discovery of active molecules with applications as antibiotics, antifungals, or anti-parasitary drugs. Omnia owns exclusive rights to patented technology developed at the Barcelona Institute for Research in Biomedicine.
- Products >** Omnia's technology applies a completely new approach to the selection of pharmacological lead compounds, based on a cellular assay that simultaneously screens compounds for several pharmacological parameters, thus accelerating and improving current methods for the discovery of anti-infective drugs. Our screens are directed against a validated target of universal distribution and they can be used to identify lead compounds against any cellular pathogen.
- Interest areas >** We are currently focused on the development of new molecules against three human infections: pneumonia caused by *Streptococcus pneumoniae*, gastric ulcer caused by *Helicobacter pylori*, and multi-resistant mycosis caused by *Aspergillus fumigatus*.
- Contact >** TEL: 934 020 158
www.omniamol.com
- | |
|--------------------------------------|
| Maurici Torra
mtorra@omniamol.com |
|--------------------------------------|



OPERON, S.A.

- Mission >** To be international leader in 6 technologies relating to In Vitro Diagnosis: Monoclonal antibodies, recombinant antigens, agglutination latex, immunochromatography, ELISA and Molecular Biology tests.
- Services >** Research, development and manufacturing of Monoclonal Antibodies and Recombinant Antigens. RD&I and manufacturing of In Vitro Diagnostic kits based on immunological reactions and molecular biology.
- Interest areas >** Industrial production and purification of monoclonal antibodies and recombinant antigens. Design and large scale production or with own brand of new In Vitro Diagnostic tests.
- Contact >** TEL: 976 503 597
www.operon.es
- | |
|---------------------------------|
| Tomás Toribio
Info@operon.es |
|---------------------------------|





ORYZON GENOMICS

- Mission >** Oryzon is a biomarker discovery company with a Diagnostic and Therapeutic pipeline focused in Oncology and Neurological disorders. Oryzon's mission is the identification of gene functions and proteins so as to design and develop biotechnological products that improve people's health.
- Services >** The company has an integrated bio-marker discovery and validation platform and develops its own core research program, with an increasing number of projects in selected niches of the biomedicine area always in partnership with the Academia and Pharmaceutical companies.
- Interest areas >** Oryzon has several important strategic alliances with food, biotech and pharmaceutical companies and is looking for industrial pharma and food partners to launch new global projects.
- Contact >** TEL: 934 037 196
www.oryzon.com

Vanessa Arroyo
varroyo@oryzon.com



PALAU PHARMA

- Mission >** Palau is a product-driven biopharmaceutical company focused on the Discovery and development of revolutionary and differentiated new medicines that are designed to address the unmet medical needs of patients suffering from inflammatory and autoimmune diseases.
- Products >** We have a broad portfolio of projects at different stages of development from early discovery to the late clinical stages, and have forged partnerships with leading pharmaceutical companies such as GlaxoSmithKline. For more information about our projects and partnerships, visit our website www.palaupharma.com.
- Interest areas >** At Palau, partnering plays a strong role in both our business model and our development philosophy. We are actively:
- Seeking innovative drug discovery alliances to jointly design and develop novel small molecule drugs based on targets and indications of common interest.
 - Pursuing partnerships in order to broaden and diversify our development pipeline through the in-licensing of new chemical entities or new formulation projects.
 - Establishing partnerships with leading biotechnology and pharmaceutical companies for the late stage development and commercialization of our projects beyond Phase II clinical trials.
- Contact >** TEL: 938 630 483
www.palaupharma.com

Heidi Sisniega
hsisniega@palaupharma.com



PAREXEL INTERNATIONAL

- Services >** PAREXEL is a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services.
- Contact >** TEL: +44 1895 614530
www.parexel.com

Georgina Singleton
georgina.singleton@parexel.com

A1. Who is who?

Company Members



PEVESA, S.L.

- Mission >** To be a reference in the design, production and R&D in the area of proteins, peptics and amino-acids and biochemical compounds employing biotechnology as a work tool.
- Products >** Proteins, peptics, biochemical products.
- Services >** Industrial Biotechnology and Biochemical Engineering. Enzyme and Fermentation Technology. RD&I Laboratories and Pilot plant
- Interest areas >** Contract manufacturing, custom made manufacturing. Product development. Collaboration, research and development agreements for new products. Joint Ventures. Investment in biotech projects
- Contact >** TEL: 955 946 024
www.pevesa.es

Iñaki Mielgo
imielgo@pevesa.es



PHARMAKINE

- Mission >** To develop products and services that foster advances in the research, diagnosis and treatment of cancer and metastasis.
- Products >** Organ-specific primary cultures, tissue arrays, cell-arrays, conditioned media, tumor spheroids.
- Services >** Preclinical evaluation of compounds with anti-tumor, anti-angiogenic or anti-metastatic activity. Oncology diagnosis support services: progression tumor markers, subclinical tumor dissemination and personalized therapy. Specialized histology services.
- Interest areas >** Development of novel anti-tumor or anti-metastatic compounds. Development of cell-based assays for preclinical evaluation of drugs. Development of advanced diagnostic systems for the early detection of metastasis. Development of advanced prognostic methods for cancer patients.
- Contact >** TEL: 94 431 70 37
www.pharmakine.com

Lorea Mendoza
lmendoza@pharmakine.com





PHARMAMAR

- Mission >** PharmaMar is a biopharmaceutical company devoted to advance cancer care through the discovery, development and commercialization of innovative marine-derived medicines.
- Products >** Yondelis®: European Marketing Authorization (MAA) granted in July 2007 for Soft Tissue Sarcoma. The MAA for the second indication of Yondelis®, ovarian cancer, will be filled to the EMEA in 2008 and Phase II clinical trials are ongoing in Prostate and Breast cancers.
Aplidin®: Positive Phase II data in heavily pre-treated, relapsed/refractory Multiple Myeloma. Orphan Drug designation by the EMEA and the FDA for Acute Lymphoblastic Leukaemia and Multiple Myeloma.
Kahalalide F: Promising clinical results from exploratory Phase II trial in severe psoriasis.
Zalypsis: Phase I trials in solid tumors ongoing.
- Interest areas >** Our business strategy relies in maintaining a strong pipeline of products in development. For the drugs in our Oncology pipeline, we seek partners for development and commercialization outside of Europe.
As well, PharmaMar is interested in licence-in Phase III or commercialize stage products in oncology haematology malignancies, to maximise our specialised commercial organization established in Europe.
- Contact >** TEL: 918 466 000
www.pharmamar.com
- Ana Benavides
abenavides@pharmamar.com



PIONEER HI-BRED SPAIN, S.L.

- Mission >** The development, production and commercialisation of agricultural seeds and inoculants for the conservation of animal fodder.
- Products >** Maize, Sorghum, sunflower, cotton, soybean, corn, lucerne, rape seeds. Lactic bacteria inoculants for animal fodder conservation
- Services >** Comprehensive agronomic services of complete advisory service to agricultural users of the plant species marketed.
- Interest areas >** The development of varieties of plant species and inoculants for agriculture and stock farming. Development of methods and knowledge concerning stock feeding. Development of varieties of plant species for human nutritional use. Development of varieties and processes for the bio-energy industry. Development of processes for improving and knowing the agricultural crop environment better (soils, waters, efficiency and irrigation methods, abiotic factors, pest control, etc.)
- Contact >** TEL: 954 298 300
www.pioneer.com
- Alberto Ojembarrena
Alberto.Ojembarrena@pioneer.com

A1. Who is who?

Company Members



PROBELTE BIOTECNOLOGIA

- Mission >** PROBELTE BIOTECNOLOGIA has been defined, right from the start, like an competitive and innovative company with the corporate purpose of researching, developing, innovating and commercialising natural bio-active principles, either, functional or technological, obtained through green technologies and, addressed to the food, cosmetic, pharmaceutical and veterinarian sectors.
- Products >** Natural bio-actives principles like POMANOX and MEDITEANOX of high concentration and purity, obtained through physical procedures. Develop of applications of the bio-actives principles for uses like either functional or technological ingredients in the food, cosmetic, pharmaceutical and veterinarian industries. Obtaining of natural and systemic vaccines for using in aquaculture; developing of effective and efficient ways of administration.
- Interest areas >** New developing of applications and uses of the bio-actives principles in the food and pharmaceutical sectors. Developing of new natural bio-actives principles through green technologies. Developing on new fish vaccines.
- Contact >** TEL: 968 307 250
www.probelte.es
- Pedro Martínez Ortiz
pedromartinez@probelte.es



PRORETINA THERAPEUTICS, S.L.

- Mission >** Development of drugs for treatment of retinal diseases.
- Products >** PRO-001. Neuroprotective agent for treatment of retinitis pigmentosa.
PRO-015. Gene therapy for treatment of retinitis pigmentosa.
- Interest areas >**
 - Novel molecules with potential ophthalmological indications.
 - Sustained release technologies for intraocular delivery of therapeutic agents.
- Contact >** TEL: 948 317 345
www.proretina.es
- Stuart Medina
stuart.medina@proretina.com



PROTEOMIKA, S.L.

- Mission >** In vitro diagnostic product development. Non-invasive biomarker discovery. New biomarker validation techniques. To provide the healthcare community with new tools in personalized medicine.
- Products >** IVD Kits in cancer and related pathologies. New serotyping tests and technologies. Therapeutic targets. Proteomic and cytomic services.
- Interest areas >** Proteomika actively seeks for industrial and institutional partners in the area of biosciences for the development of in vitro diagnostic products based on non-invasive protein biomarker detection and quantification. Collaborations with biotech companies in the fields of multiplexing platforms and instruments, immunology, microfluidics, and new high throughput biomarker discovery techniques are valued. Collaborations with applied research institutions and pharma companies committed to the development of biotechnological products in the area of interest of Proteomika.
- Contact >** TEL: 944 064 525
www.proteomika.com
- Juan Buéla
jbuéla@progenika.com





PROYECTO DE BIOMEDICINA CIMA, S.L. (BITA)

- Mission >** Managing, patenting and exploiting all the results coming out from the research activity carried out in the "CIMA project" a joint venture between a group of several first class spanish companies and the "CIMA" (Research center for applied medicine owned) by the "University of Navarra"
- Products >** See the web www.proyectobiocima.com
- Interest areas >** Licensing for the development of the results owned by the company, through licensing agreements with biotech companies or by setting up new companies to develop these results
- Contact >**
- | | |
|--|--|
| TEL: 948 287 561
www.proyectobiocima.com | Antonio Martin
amartin@proyectobiocima.com |
|--|--|



EXXENTIA, Grupo Fitoterapeutico

- Mission >** Convert ourselves into a reference for our clients in product development based on natural extracts, lipids and probiotics
- Products >** Vegetable, lipid and probiotic extracts. Exclusive product development. Technical and legal consultants. Regulatory affairs. Stability studies
- Interest areas >** Development of new bio active ingredients based on vegetable, lipid and probiotics extracts and their application in the pharmaceutical, food and cosmetic industries.
- Contact >**
- | | |
|--|--|
| TEL: 913 802 973
www.exxentia.com | José Carlos Quintela
jcquintela@exxentia.com |
|--|--|



ROCHE APPLIED SCIENCE

- Mission >** Roche Applied Science provides superior bioanalytical solutions for the life science market", the business areas offers integrated solutions for research applications, including all experimental steps that lead from sample to results
- Products >** With more than 2000 products for: Genomics: Instruments and reagents for qPCR , nucleic acid extraction and analysis, pyrosequencing and microarrays. Proteomics reagents and cellular analysis. Raw materials and industrial GMP Grade products, contract manufacturing and customized/dedicated products.
- Contact >**
- | | |
|--|---|
| TEL: 935 834 000
www.roche-as.es
www.roche-applied-science.com | Carlos Manchado-Perdiguero
carlos.manchado-perdiguero@roche.com
Neus Diez May
neus.diez@roche.com |
|--|---|

A1. Who is who?

Company Members



SEAWEED CANARIAS

- Mission >** To develop and supply our customers with all-round, sustainable, advanced technology solutions, through the industrial application of active principles from macro and microalgae
- Products >** AlgaCanTM: A range of organic biostimulants for agriculture, based on a unique combination of macro and microalgae. Algacan products are biotechnology solutions to promote growth and quality production and to protect and prevent plants from diseases and plagues. Added value additives for human and animal nutrition: compounds enriched with natural ingredients exclusive to seaweeds. Cosmetic products based on active principles from seaweeds such as antioxidants and skin firming products.
- Services >** Personal technical assistance to guarantee the best application methodology.
- Interest areas >** Innovation and development of innovating added value additives for nutrition: products that contain nutritional elements and properties exclusive to seaweeds. International distribution of ALGACAN range of products.
- Contact >** TEL: 928 184 355
www.seaweedcanarias.com
- Sergio Cáceres
scaceres@seaweedcanarias.com



SECUGEN, S.L.

- Mission >** The company's main objective is the development of methodologies for DNA analysis applied to research and genetic diagnostics tests. We market analytical applications for the diagnosis a la carte of any genetic disease using the most advanced DNA sequencing technologies, also providing a genetic counseling service. We provide molecular genetic testing services, among others, to hospitals, the pharmaceutical sector, the food sector and, in general, to all public and private research centers.
- Services >** Clinical Services: Human Genetic Diagnostics Tests. Genetic Counseling. Rare Diseases. Molecular Genetic Analysis a la carte. Molecular Biology Services: DNA Sequencing. Genetic analysis on demand (Animals, plants, microorganisms). Massive sequencing of genomes. Transcriptomics. Metagenomics. Research Services: Development of R & D projects in the field of genomics.
- Interest areas >** The company has been a pioneer in DNA sequencing and in particular in the introduction of new massive sequencing technologies and in 2007 founded the company Lifesequencing SL who settled in Spain the first massive sequencing platform's most advanced in the market, the GS-FLX (454) Sequencer, with the aim of making available to the companies and the scientific community one of the most powerful tools that currently exist for better understanding of the genomes of living organisms from man to microorganisms.
- Contact >** TEL: 918 063 105
www.secugen.es
- Begoña López Gimaré
b.lopez@secugen.es



Who is who?



SENSIA, S.L.

- Mission >** Sensia is the first Spanish Initiative to set up a leading company in the instrumentation sector for life science research laboratories and for environment measurement. Sensia develops and commercialises portable, multibiosensor systems, based on technologies developed by the Biosensors Group of the National Microelectronics Centre, belonging to the Higher Council for Scientific Research.
- Products >** SENSIA 2-SPR is an instrument based on Surface Plasmon Resonance (SPR) which enables comparative measurements to be made by incorporating channels.
- Interest areas >** The development of biosensors and their components. The development of new biosensor applications. Basic and clinical research. Diagnostic applications.
- Contact >** TEL: 918 063 089
www.sensia.es
- Juan Sebastián Ruiz
jsruiz@genetrix.es



SIGMA ALDRICH QUÍMICA, S.A.

- Mission >** Sigma-Aldrich is a leading Life Science and High Technology company. Our chemical and biochemical products and kits are used in scientific research and pharmaceutical development and our mission is to facilitate the science that makes the life better.
- Products >** Our chemical and biochemical products and kits are used in scientific research, including genomic, functional genomics and proteomic research, animal models, biotechnology, pharmaceutical development and the diagnosis of diseases: Antibodies. shRNA & siRNA. Oligonucleotides. Media, reagents and sera for cell culture. Zinc Finger Nucleases for Gene Editing. Animal Models. Reagents for iPS cells, etc.
- Interest areas >** Sigma-Aldrich has developed an aggressive initiative for the evaluation of novel technologies that can enable the scientific community. This initiative provides Sigma-Aldrich with the opportunity to continue to offer new and novel technology-based products to researchers in academic, medical and industrial institutions, throughout the world. Technologies of Interest: Functional Genomics, RNAi, Gene Editing, Cell Biology, Live Cell Biosensors, Gene Expression, Proteomics, Stem Cells, Analytical and Material Science.
- Contact >** TEL: 916 619 977
www.sigmaaldrich.com
- Javier Márquez
Javier.marquez@sial.com

A1. Who is who?

Company Members



SISTEMAS GENÓMICOS, S.L.

- Mission >** Our main activity is research, development and commercialization of analytical applications based on genomics technology. We provided high added value services and products, as well as customized R&D projects addressed to Food analysis, Human Health, Biopharmaceutical and Genomic Research.
- Products >**
- SG Food Analysis: GMO Analysis. Food Allergens Detection. Genetic Authentication in Food. Rapid Pathogen Detection. Genomic Identification and Typing. Water Analysis. Molecular Analysis Kits
 - SG Human Health: Genetic Counseling. Genetic Diagnostics. Prenatal Genetic Diagnostics. Rare Diseases. Molecular Oncology. Genetics in Oncohematology. Preimplantation Genetic Diagnosis (PGD). Molecular Diagnosis Sets
 - SG Research: DNA Sequencing. Ultrahigh throughput Sequencing Projects Bio-informatics.
- Interest areas >** Our company actively seeks the establishment of strategic alliances to promote R&D projects in Genomics. In 2008 the company has purchased the Ultrahigh Throughput Sequencing highest technology equipment available in the market: SOLID platform. And it allows us to collaborate and offering this new and exclusive technology to the whole scientific community.
- Contact >**
- | | |
|---|--|
| TEL: 902 364 669
www.sistemasgenomicos.com | Lucía Pérez Navarro
lucia.perez@sistemasgenomicos.com |
|---|--|



SOLUCIONES EXTRACTIVAS ALIMENTARIAS, S.L. (SOLUTEX)

- Mission >** Be the world-leading company in the production of ingredients by supercritical CO2 technologies for the pharmaceutical, cosmetic, nutritional, food and beverage industries.
- Products >**
- EPA (Eicosapentaenoic Acid) until 95%. DHA (Docosahexaenoic Acid) until 85%. SDA (Stearidonic Acid) until 50%. Omega-3 PUFAS until 95%. Lycopene until 50%. Terpeneless Citrus Oils in the desired folding. Sesquiterpeneless Citrus Oils in the desired folding. Terpenes. Sesquiterpenes. Magnetic Nanoparticles.
- Interest areas >** We look for partners interested in collaborating in clinical studies with products containing our ingredients. We also are interested in partnering with companies with complementary technologies with ours, in order to increase competitiveness or technological development. Of course we are always interested in establishing commercial relationships with first movers in every region/sector.
- Contact >**
- | | |
|------------------------------------|---|
| TEL: 918 060 477
www.solutex.es | Fernando G. Santos
fgsantos@solutex.es |
|------------------------------------|---|





SOM BIOTECH SL

- Mission >** Our objective is to discover, confirm, patent and develop or license the application of already known drugs in unknown indications (re-profiling). The aim of SOM is to perform at least 25 projects the first year, filing at least 6 patents and reaching licensing agreements.
- Products >** The final product of SOM is a patent of use of a new indication for a known pharmaceutical drug and the know-how developed by the company for that achievement.
- Interest areas >** The in-silico computerized platform can be dedicated to any therapeutic area. We plan strategic collaborations with in-vitro and in-vivo screening platforms and large pharmaceutical companies with commercial interest for further development of the reprofiled compounds.
- Contact >** TEL : 934 020 150
www.sombiotech.com
- Raúl Insa Boronat
insa@sombiotech.com



SUANFARMA BIOTECH S.G.E.C.R. S.A.

- Mission >** We are the first venture capital asset management company specialized in biotechnology to be authorized by the Spanish CNMV (equivalent to US SEC). We support our participated companies in several different areas, such as business and commercial activities, industrial and R&D support, as well as regulatory guidance and financial advice.
- Services >** Our first fund Suan Biotech FCR received CNMV approval in September 07, and it is authorised to raise up to 30 million euros (closing by Sept-08). The current portfolio of investments already managed by Suanfarma Biotech SGEGR SA includes five companies: Orphamed, 3P Biopharmaceuticals, Pevesa, Halotech, and Clave Suan.
- Interest areas >** SUANFARMA BIOTECH SGEGR, S.A. evaluates investment opportunities with a strong and solid science, IP and growth potential. We look for projects and opportunities within universities, tech transfer units, R&D centers and within our national biotech and pharmaceutical market.
- Contact >** TEL: 915 713 598
www.suanfarmabiotech.com
- Gonzalo Marin
gonzalomarin@suanfarma.com

A1. Who is who?

Company Members



SYLENTIS, S.A.U.

Mission > A biopharmaceutical company that is a pioneer in research and development of new drugs based on gene silencing (interference RNA, RNAi). Its main competitive advantage is efficient design of siRNAs using proprietary technology: SIRFINDER®.

Interest areas >

- Sylentis develops drugs based on RNAi technology for the treatment of diseases of high incidence in today's society. We have a strong heritage and experience in the RNAi field, as evidenced by the company's cross-functional team.
- Sylentis is focused on topical applications of RNAi: eyedrops, intranasal administration and rectal administration. Our main research projects include: Ophthalmology; we are developing treatments for glaucoma and ocular pain associated to dry eye syndrome. Inflammatory diseases. Treatment of Central Nervous System diseases. Development of formulations which increase stability and enable access to different target tissues, without the risk of secondary effects. Research of new systems for controlled release of drugs.

Contact > TEL: 918 234 553
www.sylentis.com

Ana Isabel Jiménez
ajjimenez@sylentis.com



SYNERGIA BIO

Mission > SynergiaBio is a new company whose main goal is the participation in the development and exploitation of scientific projects aimed at generating bioproducts and procedures cleaner and environmentally friendly, in accordance with a sustainable development of our environment.

Products > Synergia Bio develops research projects involved in the identification of new protocols for obtaining biomass for biofuel, development of new bio-lubricants and, in general, procedures that ensure the optimization of renewable energy generation.

Interest areas > Synergia Bio pretends to fill up the large niche that currently exists between the ideas raised in the world of academia and the major energy companies that are putting their effort in the development of renewable energy. Synergia Bio offers, on one hand, a large capacity in taking this role of intermediary between IPOs and major energy companies and, on the other hand, a high flexibility to address new scientific and technological developments to implement ideas applicable to the world of renewables.

Contact > TEL: 918 060 068
www.synergiabio.com

Roberto Clemente
rclemente@synergiabio.com





TELSTAR PROJECTS, S.A. (TPRO)

Mission > Company specializing in design, supply, installation, qualification and start up of comprehensive turnkey projects for pharma, veterinary and biotech industries according to the international regulations. To become a reference company in the biotech sector, providing added value, technology and quality in each project.

Services > Engineering and consultancy Services, Project Management, Pharma & Biotech critical facilities, Biotech Process systems.

Interest areas > Biosafety facilities, Biotech Plants, Animal House, BioBanks, R+D centers, Diagnosis, Pharmaceutical Production Plant, API's Production Plant.

Contact > TEL: 913 717 970
www.tpro.es

Javier Ballesteros Cherp
jballesteros@tpro.es



THROMBOTARGETS EUROPE, S.L.

Products >

- Pipeline (13 products): Antihemorrhagic Program: TT-103MH, TT-111, TT-112, TT-125, TT-126. Anticoagulant Program: TT-105, TT-120 TT-123, TT-124 Antiplatelet Program: TT-113, TT-114, TT-115. Fibrinolytic Program: TT-116.
- Technological Platforms: BioplatfromScreen (ultra HTS), Recombinant Nanotransporters (NTR) (vehicles for therapeutical agents). Genetic Therapy (NTR containing genetic material)

Interest areas > Our areas of interest are Pharmaceutical Development and HTS
Until that moment we have maid alliances with: 6 Spanish Public Centers, 4 of which Universities. 3 International Public Centers - 2 in the USA and 1 in Brazil. 7 Spanish Private Companies. 3 International Private Companies - Russian, Dutch and North American

Contact > TEL: 934 463 016
934 509 760
www.thrombotargets.com

Dr. Ignasi Miquel
ignasimiquel@thrombotargets.com



VALENTIA BIOPHARMA

Mission > Biotechnology Company focused on the Development of New Drosophila models of Genetic Human Diseases, and Drug Discovery using Automated in vivo Screening Technologies in Drosophila melanogaster models.

Products > Know-how and Biotechnology on the custom-made Design of Human diseases in Drosophila ;Drug Screenings on in vivo and in vitro Drosophila models; Biosafety evaluation of chemicals for the European REACH regulation; Evaluation of Healthy Properties in nutritional products.

Interest areas > ValentiaBP is strongly interested in setting up collaborations with Bio-Pharma for the Development of Screening Platforms based on Drosophila possible models; Become and active participant of Networks Institutions interested on Rare Diseases (RD) Research and; Establish Collaborations towards offering a consolidated joint portfolio of analytical tests for the European REACH regulation.

Contact > TEL: 963 543 842
www.valentiabiopharma.com

José R. Tormo
jrtormo@valentiabiopharma.com

A1. Who is who?

Company Members



VIDACORD, S.L.

- Mission >** To process and criopreserve the cord blood that parents entrust VidaCord. To offer their children in the future the possibility to use these cells or their derivatives to treat certain diseases.
- Services >** Obtaining, processing and criopreserving stem cells from blood cord.
- Interest areas >** Cell Therapy. Regenerative Medicine.
- Contact >** TEL: 917 026 879
www.vidacord.es
- Angel G. Alvarez Ramos
agar@vidacord.es



VIRCELL, S.L.

- Mission >** To produce quality reagents and to develop innovating products that imply significant advances.
- Products >** Cell Culture: Cell lines, monoclonal antibodies, means of transporting virus. IFI: Immuno-fluorescence kits (single test and multitest). Brucellacapt: Diagnosis of Brucellosis. ELISA: Kits for the detection of specific antibodies. Controls of DNA/ RNA: controls of PCR freeze-dried for an extensive range of infectious agents.
- Contact >** TEL: 958 441 264
www.vircell.com
- Almudena Rojas
arojas@vircell.com



VITA AIDELOS

- Mission >** Crear una percepción social positiva hacia la biotecnología, manteniendo el rigor científico. Colaboran con fundaciones, museos y espacios de la ciencia y divulgan los avances científicos en materia de biotecnología, favoreciendo la alfabetización científica y una actitud crítica desde el conocimiento.
- Products >** Patents, know-how. Practice Kits in Biotechnology: Molecular Biology and Microbial Biotechnology. Multimedia Products. Services: Spreading and qualification in Biotechnology Practical consultancy. Taking part in events and activities aimed at spreading Biosciences.
- Interest areas >** Commercialization agreements. Taking part in R & D & I projects. Projects aimed at spreading science.
- Contact >** TEL: 944 069 689
www.vita-aidelos.com
- Melania Rosique
info@vita-aidelos.com



Who is who?



VIVACELL BIOTECHNOLOGY ESPAÑA, S.L.

Mission > VIVACELL BIOTECHNOLOGY ESPAÑA S.L. is a company focussed in Biomedicine and Pharmaceutical Chemistry that investigates in new medical products derived from medicinal plants. The activities of the company are concentrated in the preclinical phase of drug discovery. We have developed our own platforms of primary screening for plant extracts.

Products > Vivacell owns a large collection of plant-derived extracts biologically tested and a library of natural compounds. We have developed CDE-001, an standardised phytoextract with application in colon cancer and inflammatory bowel disease. In addition the company provides specialised in vitro and in vivo models for testing and developing pharmaceutical, nutraceutical and phytopharmaceutical compounds.

Contact >	TEL: 957 290 666 637 774 192 www.vivacellspain.com	Dra. M.Luz Bellido Cabello de Alba m.bellido@vivacellspain.com
---------------------	--	---



VIVIA BIOTECH

Mission > Vivia Biotech is dedicated to the research of new indications for existing drugs ("reprofiling") in less common diseases (commonly known as "rare diseases"), in the most simple and direct way, but that had not been possible until now: analyzing by means of a pioneer proprietary technology ("ExviTech") the effect of thousands of existing drugs directly on a patient's standard biological sample while it is still fresh (24/48 hours).

Products > Vivia Biotech Centers its operations on the following areas of research. Hematological Neoplasias (Leukemia and Myelodysplastic Syndrome): More than 100.000 potential new treatments will be evaluated during the next 1.5 years directly in patient samples. Combinatorial Cytomic Biomarkers. Development of cytomc biomarkers of chronic stress and depression on clinically characterized human samples.

Interest areas > • Hematological Neoplasias (Leukemia and Myelodysplastic Syndrome). Chronic Stress and Depression.

Contact >	TEL: 952 278 916 www.viviabiotech.com	Juan Ballesteros (Presidente) jballesteros@viviabiotech.com Isabel Pulido (Secretaria) ipulido@viviabiotech.com
---------------------	--	--



VIVOTECNIA RESEARCH S.L.

Mission > Vivotecnia performs pre-clinical research on a contract basis. We offer reliable high quality investigation for the cosmetic, pharma and biotech industry.

Services > We offer solutions to research and development projects. We can perform a wide range of efficacy and toxicity studies. We are certified to work under GLP standards and can work with rodents, non rodents and dogs as required by FDA, EMEA and the rest of agencies around the world.

Interest areas > Activity, efficacy and toxicity studies in vitro and in vivo models. Managing services for animal facilities and animal models. Animal facility services and rooms to rent.

Contact >	TEL: 917 280 715 www.vivotecnia.com	Antonio Vila Coro vilacoro@vivotecnia.com
---------------------	--	--

A1. Who is who?

Company Members



ZELTIA

- Mission >** Zeltia is an outstanding reference in the improvement of well-being through the fight against cancer, nervous system degenerative diseases and other diseases. We have therefore taken up the challenge of pre-empting the future, and this is only possible through constant innovation, with an R&D policy that has positioned us as one of the top eight Spanish companies in R&D investment. The companies comprising the Group: Pharmamar S.A, Neuropharma S.A, Genómica S.A.U, Xylazel S.A and Zelnova S.A
- Services >** The discovery and development of drugs of marine origin, news, scientific publications
- Interest areas >** Zeltia since its beginnings has collaborated and continues collaborating actively with academics and public centers, with same and large businesses of the sector biopharmaceutical and of the chemical, so much national as international sector.
- Contact >** TEL: 914 444 500
www.zeltia.com
- Carmen Eibe
ceibe@zeltia.com



ZF BIOLABS, S.L.

- Mission >** One of the first European biotechnology companies specialized in the use of the zebrafish (Danio rerio) as an alternative model for toxicology and biomedical research. The zebrafish embryo is becoming one of the most important biomedical and toxicological models due to its main advantage of being a whole vertebrate organism but small enough to be handled in multiwell plates.
- Products >** ZF Tox Ready to use Kits. Supply of embryo and larvae; world leading embryo production technology. Custom designed aquarium modular systems. Specific feeds
- Services >** Toxicity: acute, teratogenicity, organ-specific toxicity, toxicogenomics, ecotoxicology, nanotoxicity. Disease models & genomic tests: RT-PCR, gene silencing, targets, transgenics. Zebrafish facility set-up service. R&D Projects On-Demand.
- Interest areas >** Epigenetics, anti-ageing, toxicity (toxicogenomics, nanotoxicity, ecotoxicity, etc.), animal models for human diseases, functional genomic studies, screening of compounds, contract research organization, FP7 projects.
- Contact >** TEL: 918 049 020
www.zfbiolabs.com
- Joaquín Guinea López
info@zfbiolabs.com



A1. Who is who?

Other Organizations Members



Association of Bioenterprises of Valencian Community Region (BIOVAL)

Mission > Bioval is a meeting platform for the biotechnological sector in Valencian Community region. Our objective is to promote and support the growth and cooperation of the biotechnological sector in our region. Bioval gathers private companies, research centres, universities, hospitals and other organizations where R+D activities are related to biotechnology.

Services > Information to their members, promotion of the biotechnical sector of the Valencian Community, promotion of the associate entities, promotion of this sector by means of an active presence in the media, trade exhibitions and different forums, foment of the innovation in the sector, impulse to technological transfer, representation of the this sector interests before Civil Services..

Contact > TEL: 902 889 990
www.bioval.org

María Eugenia Hernández de Pablo
info@bioval.org



Fundación Aula Dei
PARQUE CENTRICO TECNOLÓGICO
AGROALIMENTARIO

AULA DEI FOUNDATION SCIENCE AND TECHNOLOGY PARK

Mission > To connect de research centres and the companies. To support and encourage the companies within the agricultural and environmental sector to look for scientific and technological solutions. To transfer the results of the research centres linked to the Park to the production fabric. To spread the researchers work to enhance its visibility. To arrange and promote the existing technology offer. To detect and give solution to the new technologies needs. To encourage the creation and consolidation of innovative companies within the sector.

Services > Management of R + D + i contracts between companies and research centres. Advice regarding R & D projects. Business incubator. Innovation and Creation of new technology based firms Programme. Spin off Programme. Cooperation networks for knowledge and technology transference. Transferring and putting the technology on the market. Regional, National and International Financing of R + D + i projects. Training: specialised postgraduate and advanced courses for professionals.

Interest areas > Animal Health and Production. Environmental Technology. Forest Resources. Freshwater Resources and irrigation technology. Agricultural Economy. Vegetal health and Nutrition. Food quality and security technology. Biotechnology. Genetic Improvement. Agrifood production and container. Bio-mass. Wine technology

Contact > TEL: 976 716 976
www.pctad.com

Susana Martínez Hernández
smartinez@aragon.es





BioBasque, the Basque BioRegion

Mission > To develop a new business sector related to life sciences, contributing to diversify the current industrial tissue and to maintain competitiveness in an international context.

Products > BioBasque is represented by the BioBasque Agency, a one-stop location for biosciences in the Basque Country, and the instrument created to implement the strategy and to co-ordinate the relevant stakeholders.

Interest areas > BioBasque is interested in establishing contacts with equivalent organisations, and other type of entities, that contribute to support the growth of the biocluster. It is equally interested in contacting companies wishing to establish operations in southern Europe.

Contact > TEL: 946 555 155
www.biobasque.org

Dr. María Aguirre
biobasque@spri.es



BIOIBAL (The Balearic Islands Biotechnological and Biomedical Cluster)

Mission > BIOIBAL's mission is to promote biotech sector in Balearic Islands and help to create a suitable environment for adding value in Balearic research. Identify projects to increase biotech companies competitiveness and generation of public-private initiatives

Competences and fields intervention: Fostering relationships and synergies between all the stakeholders located in the area and encourage networking with other clusters and agencies. Internationalizations, promotion the participation of Balearic island companies in International fairs and congresses in the sector.

Services >

- Research and Knowledge consulting for its members: Organize government subsidies, research grants and other sources of financing. Organize biotechnological events. Provide an employment and internship database to assist both employers and possible candidates. Offer consulting services on technical, legislative and market aspects. Promote internationalization and the establishment of alliances and R&D collaborations
- Assistance on the creation of SME's biotechnology companies.
- Represent the sector's interest in front of Governmental agencies.
- Facilitate the transfer and implementation of biotechnology into sectors where it is traditionally used as well as untraditional sectors.

Contact > TEL: 871 230 022
www.bioibal.org

José Luís Pons Hinojosa
info@bioibal.org

A1. Who is who?

Other Organizations Members



Centro Nacional de Investigaciones Oncológicas, CNIO (The National Oncological Research Centre)

Mission > Basic and applied research under an integrated approach, fostering the interaction of basic research with of molecular diagnostics programmes and of the discovery of new drugs, all supported by a solid equipment and technical services infrastructure.

Services > Undertaking research to enable the new, more efficient diagnosis and treatment methods to be obtained for oncological diseases. The transfer of scientific knowledge into clinical practice, so that scientific progress has an effect on our healthcare system as early as possible, and thus on patient welfare. The transfer of technology developed in the CNIO to innovating companies. To set up a new and more effective management system in the European scientific environment.

Contact > TEL: 912 246 900
www.cnio.es

José Ignacio Fernández Vera
vera@cnio.es



BIOREGIÓ DE CATALUNYA (BIOCAT)

Mission > Biocat is the Catalonia biocluster organization with the aim to promote biotechnology and biomedicine in Catalonia. It is fostered by the Government of Catalonia and it is participated by companies and public research institutions

Services > Our main goals are: Facilitate networking among the different stakeholders. Foster biotechnology as a key economic driver for the country. Promote Catalonia biotechnology at the world stage. Inform and contribute to a better understanding and perception of biotechnology.

Contact > TEL: 933 103 330
www.biocat.cat

Montse Daban
mdaban@biocat.cat



Who is who?



CIBER-BBN

Mission > To increase research capabilities of the component groups (sharing resources, coordination and promotion of synergies). To enhance greater and better use of advanced technologies in the National Health System. To improve the technological level of national industry in this field. To favour the emergence of specialists with a high level of training in health technologies. To increase the presence of Spain in decision-making forums and international research networks in this field.

Products > Intelligent platform for a drug-free prevention of diabetes mellitus and cardiometabolic risk. Multimodal biomedical information integration toolkit, bio-modeling and biosimulation techniques. Development of new concepts of scaffoldings and cell cultures for regenerative medicine, with applications in the vascular system, abdominal hernias.... Enzyme replacement therapy in Fabry's disease. Obtaining biosensors for identifying pathogenic microorganisms with diagnostic uses. Development of molecular imaging strategies and of in vivo animal model phenotypes of human pathologies. Translational extension to patients

Interest areas > BIOENGINEERING AND BIOMEDICAL IMAGING: Multimodal diagnosis. Intelligent devices. BIOMATERIALS AND TISSUE ENGINEERING: Regenerative medicine (Scaffold-based Tissue Engineering; Cell therapy; Cell biophysics). Endoprostheses and implants. NANOMEDICINE: Molecular diagnosis and biosensors. Therapeutic nanoconjugates and drug delivery systems.

Contact > TEL: 976 512 368
www.ciber-bbn.es

Gonzalo Vicente Lacambra
gvicente@ciber-bbn.es



CENTRO NACIONAL DE TECNOLOGÍA Y SEGURIDAD ALIMENTARIA – LABORATORIO DEL EBRO (CNTA)

Mission > CNTA contributes to the development of the agri-food industry, providing enhanced technological services through Quality and Innovation under the principle of food safety. This goal is accomplished by providing the agri-food sector with services and technical support to improve their and competitiveness and innovation capacity in order to produce safer and healthier foods.

Products > Analytical control for processes and product improvement. Assistance in the implementation Food Safety and Quality Systems (FSQS). FSQS monitoring and assurance. Process Audits. Specialised training of technical/managing personnel. Development of R&D&I projects both individually and in collaboration with Industries, Universities and other Research Organisations, etc. Technological Consulting

Interest areas > Starter culture development (novel processes, improved performance, novel starters...). Development and assessment of novel Probiotics. Development of natural functional additives through clean technologies (biotechnology, bacteria, yeasts...). Development and assessment of functional foods. Cell Models, animal, nutrigenomics.

Contact > TEL: 948 670 159
www.cnta.es

Carlos González Navarro
cgnavarro@cnta.es

A1. Who is who?

Other Organizations Members



CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC)

- Sector >** Investigación Científica.
- Mission >** A public research body, under the auspices of the Spanish Ministry of Science and Technology, that provides research capacity and human resources and materials in the development of new scientific knowledge and the transformation of these into processes and products of social and economic interest.
- Services >** To draw up and execute scientific and technological research projects. To draw up and execute collaboration contracts and agreements with companies and with other social agents. To contribute to the analysis and selection of future scientific and technological aims and to advise public administrations on research and technological innovation matters. To foster progress in basic and applied research. To collaborate with the Regional Governments in subscribed research activities. To collaborate with the universities in research and higher education activities. To develop training programmes for researchers and technicians working in the field of science and technology. To collaborate with the National R&D Plan in advisory and management tasks commissioned and with the Regional Governments who request this in the undertaking of their science policies.
- Interest areas >** Projects in all the biotechnology and biomedicine areas and at the interface between biotechnology and organic chemistry, analytical chemistry, food technology, applied physics, etc. Collaboration with universities, technological centres, industries, etc. to enhance the flow that transforms basic science into social well-being.
- Contact >** TEL: 915 855 301
www.csic.es
- Prof. José M. Guisán Seijas
ott@csic.es



CIBER-ER

- Mission >** CIBERER's main objective is to become an international reference centre for research on rare diseases, with emphasis on translational research. The scientific knowledge generated by the groups in CIBERER is intended to be applied in clinical practice in the patient's benefit.
- Services >** The CIBERER main services are related to: Collaborative research projects on rare diseases. Research platforms infrastructures. Knowledge/Technology transfer.
- Interest areas >** Genetic and molecular diagnosis. Development of advanced therapies. Gene therapy and cell therapy. Clinical trials and orphan drugs. Training Programmes. Research collaborative projects.
- Contact >** TEL: 963 394 789
www.ciberer.es
- Ingrid Mendes
imendes@ciberer.es



Who is who?


FUNDACIÓN MEDINA (Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía)

Mission > Fundación MEDINA is a non-profit public-private partnership between Merck Sharp and Dohme de España S.A., the Junta de Andalucía and the University of Granada, to discover innovative compounds and therapies for unmet medical needs.

Products > New leads from microbial natural products collections in therapeutic areas identified as top priority by the national and regional Spanish Health Systems. Highly automated screening platform: evaluation of potential cardiovascular toxicities and adverse drug metabolism effects (ADME/TOX) of drug candidates in development. Ion channels assays (hERG, Cav1.2, Nav1.5). Drug metabolism assays (CYP inhibition and induction). Off-target interactions (neurotransmitter receptors, PPARs).

Interest areas > Discovery of novel therapeutics from microbial natural products collections in: infectious diseases (including tuberculosis and parasitic diseases), oncology, immunoregulation and rare diseases. Study of potential cardiovascular and neuronal safety risks, and drug-drug interactions of new leads in early stages of the drug-discovery process.

Contact >	TEL: 958 993 965 www.medinaandalucia.es	Olga Genilloud olga.genilloud@medinaandalucia.es
---------------------	--	---


FUNDACIÓN GAIKER

Mission > GAIKER is a Technology Centre whose objectives are to carry out research and supply reliable, innovative technological solutions which give value to the company, contributing to its technological development and its competitiveness through the generation, gathering, adaptation and transfer of innovative technologies in a sustainable manner. It also assumes the development of opportunities in emerging economic activities, all within a framework of collaboration with other agents.

Services > Cell culture. Proteomics/ Genomics. Microbiology. Fluorescence Microscopy. Surface Plasmon Resonance (SPR). Applied Molecular Biology (PCR, RT-PCR, etc.). In order to carry out In Vitro Toxicology studies in pharmaceutical products, we have the Good Laboratory Practice Certificate (GLP). We are mainly focused on Health, Pharmaceutical, Food, Fine Chemistry and Agriculture, Industrial Chemistry and Services sectors.

Interest areas > Our main fields of work are the following: Biodetection systems: BioRecognition molecules immobilization processes on surfaces. BioDetection systems development. Identification and development of target molecules. Omics: Genomics. Proteomics. In Vitro Test: Efficacy evaluation. ADME. Toxicity of drugs and nanoparticles.

Contact >	TEL: 946 002 323 www.gaiker.es	José María Goenaga mark@gaiker.es
---------------------	-----------------------------------	--------------------------------------

A1. Who is who?

Other Organizations Members



FUNDACIÓN PARQUE CIENTÍFICO DE MADRID (PCM)

Mission > To foster scientific research.

Services > • Business Development: Support for entrepreneurs, Business Creation, Business Incubator, Bioincubator, Access to financing, scientific and university environment. Scientific Services: Genomics, Proteomics, Micro-analysis of materials, Bio-IT, Biotransformations, Animal Health Care.

Interest areas > The creation of companies with a technological base. Science services to biotech companies. Large scientific facilities. Technical assistance for the creation and management of science and technology parks.

Contact > TEL: 91 497 24 00
www.fpcm.es

Antonio R. Díaz
parque.cientifico@pcm.uam.es



FUNDACIÓN PARQUE TECNOLÓGICO DE CIENCIAS DE LA SALUD DE GRANADA (PTS)

Mission > PTS Granada is a model for the transfer of basic clinical Research and Technology in the field of health and biomedicine which contributes to economic development via: The promotion of interdisciplinary research in biomedicine at an international level. The protection and transfer of knowledge. The consolidation of health sciences business framework based on technology and aimed at clinical practice. Being a centre of excellence for healthcare.

Services > • RESEARCH SERVICES: Library, Cell Culture, DNA Sequencing, Genomics and Proteomics, Oligonucleotide Synthesis. SERVICES OF TECHNOLOGICAL INNOVATION: Funding of the I+D+i, Transfer of Technology, Industrial Property, Technological Alertness. MANAGERIAL SERVICES: Services of EIBTs's creation, Services of incubation, Services of managerial development. GENERAL SERVICES: Security, Restaurant, Advisory and Consultation, Marketing and Advertising, Hotels, Healthcare Services, Business Associations, University of Granada, Bioincubator, Technological Innovation Network (RETA), Patents Centre (CIT-PIA), Innovation Centre, Creation of technology-based companies, Technological trampoline network (CESEAND, RTT), Business Development Support Centre (CADE)

Interest areas > Biotechnology and Human Health

Contact > TEL: 958 535 050
www.ptsggranada.com

Jesús Quero Molina
jquero@ptsggranada.com



Who is who?



FUNDACIÓN INBIOMED

Mission > Development of new products and medicines for cellular therapy. Development of genomic, proteomic and gene silencing technology in stem cells. Identification, characterization and growth of adult stem cells.

Services > Inbiomed offers research services for companies and investigators based on the use of stem cells related with research programs being undertaken in Inbiomed. Inbiobank: Human stem cell bank. Inbiopharma: Pharmaceutical laboratory. Technology Services: Contract research.

Contact > TEL: 943 309 064
www.inbiomed.org

Jose Manuel Franco
inbiomed@inbiomed.org



GENOMA ESPAÑA

Mission > Promote the creation of value from knowledge in strategic areas of the National R&D&I Plan, especially in biotechnology, through technology transfer and training with the goal of improving the health and quality of life of citizens and the competitiveness of businesses, while establishing the framework for public-private partnerships.

Services > • Our main goals are: Promote the active support and coordination of research carried out in Spain. Make better use of research resources and results by promoting technology transfer and supporting the creation of technology-based companies. Undertake tasks of technology watch, prospective and strategic analysis. Help in the internationalization and in the promotion of the Spanish biotechnology sector. Bring biotechnology closer to society.

Contact > TEL: 914 491 250
www.gen-es.org

Belén Gilarranz
belen.gilarranz@gen-es.org

A1. Who is who?

Other Organizations Members



INSTITUTO ANDALUZ DE BIOTECNOLOGÍA (IAB)

- Mission >** The IAB is a body of the Department of Innovation Science and Enterprise, having among his objectives to promote and to dynamize Biotechnology in Andalusia from fields of Investigation, Technology Transfer and Enterprises. The IAB coordinates and promotes collaboration of all implicated agents in the biotechnological sector, optimizing available resources.
- Products >** The IAB, currently has assigned 60 Andalusian Research Groups, belonging to all Andalusian Universities.
- Services >** Participating in the elaboration of Action Plans in Biotechnology. Elaborating reports on status of the Biotechnological Sector. Promoting and dynamizing the biotechnological transfer. Serving back-up and supporting research groups. Elaboration and diffusion of technical specialties of research groups and patent technical specifications. Helping in the search and member selection for business opportunities. Spreading and promoting the Biotechnological Sector in Andalusia: Conferences, Courses, Events, etc.
- Interest areas >** Agriculture / Forestry. Stockbreeding / Aquaculture. Diet. Health. Methods for detection and diagnosis of illnesses. Regenerative medicine. Obtainment of molecules of clinical or pharmacological interest. Environment and Energy. Bio-computer science. The IAB has a technological portfolio of more than 40 biotechnological patents ready to be marketed, which are classified by market segments in which they apply.
- Contact >** TEL: 952 134 183
www.iab.cica.es
- Fernando Pliego Alfaro
iab-secretaria@uma.es



INSTITUTO DE SALUD CARLOS III

- Mission >** A public research body belonging to the Spanish Ministry of Health and Consumption, whose mission is to foster, develop and render technical scientific services in the field of human health care.
- Services >** Research into the different aspects relating to the application of genetic knowledge in diagnosis, therapy, the development of new drugs and epidemiology. The development of innovation in telematics, bio-IT, genomics and proteomics and other new technologies applied to health care. The conservation of international standards and the preparation and conservation of national standards. Awarding aid and subsidies for biomedical research. Drawing up reports about healthcare technologies and services aimed at consolidating decision-making at the different levels of the National Healthcare System.
- Interest areas >** Molecular Diagnosis. Telematics and Bio-IT. Proteomics and genomics. Healthcare technologies.
- Contact >** TEL: 918 222 125
www.isciii.es
- Julia Medrano Chivite
otri@isciii.es



Who is who?



IRB LLEIDA

Mission > The aim of IRBLleida is to promote, develop, transfer, administer and spread biomedical research and research training in life sciences and health fields.

Services > Collaborative research and development projects.
Clinical trials

Interest areas >

- Biotechnology and Human Health Care
- Health Food and Nutrition
- Collaborative research projects
- Clinical trials

Contact > TEL: 973 702 201
www.irblleida.cat

Santiago Planas i Martí
splanas@pcital.es



Industria, Innovación
y Empleo

LA RIOJA GOVERNMENT. DIRECTORATE-GENERAL FOR INNOVATION

Mission > R+D and Innovation Policies Design. Communication of the relevance of the R+D and Innovation issues. Regional coordination of those activities. Push up of the technology transfer. Facilitate the growing up of new innovative companies. Enlarge the research activity in La Rioja. Be in the European R+D and Innovation Network. Focus the local companies to the new technologies to improve their competitiveness.

Services > New Third R+D and Innovation Regional Plan 2.008-2.011. New Regional Law for R+D and Innovation. Technology Surveillance and Prospective. Support our companies to participate in R+D and Innovation projects. Develop activities to transfer the biotechnological solutions to traditional companies. Helping companies to reach funds for biotechnological projects. Coordination of the Technologies Centres in La Rioja. Communicate to a public of all ages the relevance of the biotechnology.

Interest areas > All related to the above mentioned objectives.

Contact > TEL: 941 291 684
www.larioja.org

Javier Ureña Larragán
dg.innovacion@larioja.org

A1. Who is who?

Other Organizations Members



PARC CIENTÍFIC DE BARCELONA (PCB)

Mission > To potentiate quality research with the support of a wide range of technologies. To revitalize the relation between university and business. To promote the creation of new companies and institutions. To further the science-society dialogue and encourage careers in science

Products > Technological facilities by Technology Platforms and Scientific Services of the PCB and UB. Independent access to equipment. Consultancy/ assessment service. Co-Development of specific techniques. Sub-contracting of services. Custom-designed research services Partnership in research projects. Innovation. Consultancy/ assessment service. TTO. Business Creation Center. Patent Center. Valorization and Licenses (AVCRI). General services: Reception, Meeting rooms, Auditorium, Cafeteria / Res-taurant, Congresses and Meetings Unit, Research Pro-jects Management Unit, science promotion, networking, etc..

Interest areas > Medicinal chemistry, nanotechnology, structure-based drug discovery, ecotoxicology, proteomics, transcriptomics, animal models of disease.

Contact > TEL: 934 034 475
www.pcb.ub.es

Fernando Albericio
administracio@pcb.ub.es



UNIVERSIDAD AUTÓNOMA DE BARCELONA. Parc de Recerca. Oficina de Innovación, Traducción y Creación de Empresas

Mission > To foster the entrepreneurial spirit within the UAB. To foster the creation of an entrepreneurial centre in order to attract innovating projects from entrepreneurs within the sphere of the UAB in their most embryonic stages and to support them during their creation period until they become competitive companies going on to form part of Catalonia's business fabric.

Products > To support the execution of business plans from UAB entrepreneurs. Personal accompaniment and coaching. Specific training in the area of entrepreneurship. Seeking financing for business initiatives. To support project viability during the established creation period. Consolidation of human capital and setting up of strategic alliances. Management and co-ordination of UAB company nurseries: Masia Can Fatjó PTV, UAB Company Nursery. Biotechnology and Biomedicine to Biocampus Company Nursery VE3B). Partner Centre Nurseries: National Micro-electronics Centre, Computer Viewing Centre, Artificial Intelligence Research Institute. Matas, an economic interest group based on research into materials and gases. Internationalisation and networking.

Contact > TF: 935 814 235
www.uab.es

Sònia González
sgonzalezg@uab.cat



Who is who?



SOCIEDAD ESPAÑOLA DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR (SEBBM)

- Mission >** Created in 1963 and with more than 3500 members, has the following objectives: i) promoting research; ii) boosting transfer of knowledge to the industry; iii) improving teaching; iv) facilitating contacts with interested stakeholders; v) fostering the internationalization of Spanish science; vi) informing the Spanish society about scientific progress; and, vii) contributing to strengthen the social and economical influence of Science.
- Services >** Technology development and transfer in biochemistry and molecular biology and biotechnology. R&D Research in Biochemistry and molecular biology and biotechnology. R&D training in Biochemistry and molecular biology and biotechnology. R&D services in Biochemistry and molecular biology and biotechnology.
- Interest areas >** To promote transfer of results and technology between members of the Society and partners of ASEBIO. To co-organize courses, workshops of interest in Biotechnology. To participate in Congresses and Meetings in Biotechnology
- Contact >** TEL: 915 613 381
www.sebbm.es
- Isabel Perdiguero
sebbm@sebbm.es



CENTRO TECNOLÓGICO LEITAT

- Mission >** LEITAT Technological Centre aims to provide R+D+i added value to products and industrial processes in the biomedical, oncology, bio and nano bio-technology sectors amongst others. In addition to the promotion of R+D+i, LEITAT's objectives are the technology transfer and scientific development under innovation, sustainability, responsibility, integrity and independence criteria.
- Products >** Generation of monoclonal antibodies. Drug repositioning. In vitro and in vivo pharmacological characterization of therapeutic agents. Identification and validation of new biomarkers. Design and characterization of tools, instruments and devices for diagnosis, prognosis and monitoring. Characterization of antimicrobial properties, antifungal and anti dust mite. Determination of drug levels in biological fluids. Determination of inorganic nanoparticles by ICP-MS.
- Interest areas >** Therapy. Design and application of bioprocesses on industrial environments. Extraction of active ingredients of microalgae and renewable sources for food, cosmetic and pharmaceutical industries. Synthesis and processing of biopolymers. Toxicology and ecotoxicology of nanoparticles
- Contact >** TEL: 937 882 300
www.leitat.org
- Joan Parra
info@leitat.org

A1. Who is who?

Other Organizations Members



NEIKER - Instituto Vasco de Investigación y Desarrollo Agrario

- Mission >** NEIKER is a Public Institute of Research and Technological Development that seeks generating knowledge and offering services that contribute to the improvement of Agriculture, Food and Environmental sectors. Biosciences and biotechnology are the instruments with which to contribute actively to the economic and social development, improving competitiveness and sustainability.
- Services >** Activity is focused on R&D, laboratory analysis, technical advice for the Agricultural, Food and Environmental sectors, technical support under emergency alerts, new technology transfer to emerging companies and development of new technology-based companies. Main working fields: genomics, in-vitro cultures, identification and production of biomolecules, food biosecurity, application of biotechnology to animal health and environment.
- Interest areas >** Industrial applications for new biomolecules. New applications of genomics and in-vitro cultures. New drug development for the Animal Health sector. Diagnosis in Food biosecurity. Systems of environmental evaluation.
- Contact >** TEL: 944 034 300
www.neiker.net
- Susana Hormilla
shormilla@neiker.net



UNIVERSIDAD DE NAVARRA

- Mission >** Higher education, basic and applied research and specialized medical attention.
- Contact >** TEL: 948 425 400
www.unav.es
- José Manuel Zumaquero y María Font
mzumaquero@unav.es



UNIVERSIDAD EUROPEA DE MADRID

- Mission >** • Providing students with an excellent university education in order to acquire both academic knowledge and practical skills which will allow them a rapid incorporation into the professional world. Promoting an international perspective by encouraging students to study at Universities abroad and facilitating internships in foreign companies
- Services >** • A university education that includes Bachelor's and Graduate Degrees in a broad range of programs. Bachelor's Degrees and Double Degrees are offered in Pharmacy and Biotechnology, in Health and Biomedical sciences area. Their cutting-edge practical approach prepares students to work both in research and management of biotechnology companies.
- Interest areas >** Internships required for students in their final year of studies in Biotechnology companies. Undergraduate and Graduate training in Biotechnology: courses, seminars, etc. Collaboration agreements with private companies to develop research projects at UEM Laboratories.
- Contact >** TEL: 912 115 277
http://www.uem.es
- Maria Junco
maria.junco@uem.es



Who is who?



UNIVERSIDAD PABLO DE OLAVIDE

- Mission >**
- To achieve such a research dimension that constitutes an outstanding reference at the international level
 - To promote both technology transfer and wealth development
 - To support innovation
 - To promote social development
- Services >**
- Education and Training
 - Research
 - Advice on business administration and management
- Interest areas >**
- Collaboration with university research teams.
 - Collaboration agreement for professional training of students and graduates of the university.
 - Location of entrepreneurial firms in the UPO campus.
- Contact >**
- | | |
|--------------------------------|---|
| TEL: 954 977 814
www.upo.es | Cristina Moreno
planestrategico@upo.es |
|--------------------------------|---|



VETERINDUSTRIA

- Mission >**
- To defend the collective interests of the associated companies that manufacture and/ or commercialise the following products and services in Spain: Veterinary medicines, animal healthcare and nutritional products and additives for animal nutrition, through its different co-ordination, advisory and communication services, to thus promote all the aspects of the Animal Healthcare and Nutrition Industry, benefiting both the sector and society in general.
- Contact >**
- | | |
|--|---|
| TEL: 913 692 134
www.veterindustria.com | Santiago de Andrés
veterindustria@veterindustria.com |
|--|---|

